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“It’s the terror of knowing what this world is about” 
D. Bowie, F. Mercury 
To Dana, Evelina and David 

Abstract 
Neo-adjuvant radiotherapy (RT) in rectal cancer (RC) reduces the risk for local recurrence (LR). The 
optimal fractionation or time to surgery is not determined. The focus areas of this thesis are different 
RT-courses and timing of surgery in patients with RC. The Stockholm III trial forms the basis of the 
studies included in the thesis. Between 1998 – 2013, patients with primarily resectable adeno-
carcinoma of the rectum were randomly allocated to three different RT-courses. SRT - 5 Gy x 5 and 
surgery within one week, SRT-delay- 5 Gy x 5 and surgery after 4-8 weeks or LRT-delay - 2 Gy x 25 
and surgery after 4-8-weeks. Including centres could choose to randomise patients between three 
courses or between the two courses with 5 Gy x 5. Primary endpoint was time to LR, secondary end 
points included distant metastases (DM), survival, tumour regression and adverse events. All patients 
have been registered in the Swedish ColoRectal Cancer Registry. 
Paper I. All 840 patients randomised in the Stockholm III trial were analysed after a minimum 
follow up of 2 years. 357, 355 and 128 patients were allocated to SRT, SRT-delay and LRT-delay 
respectively. The three armed randomisation was analysed separately and the patients randomised to 
any of the courses with 5 Gy x 5 were pooled and analysed in a short course RT comparison. About 
6 -7 % of the patients with a delay to surgery required hospitalisation between start of RT and surgery 
due to RT-induced toxicity. In total, 25 patients had a LR within the follow up time, without statistical 
significant differences between the groups. The cumulative incidence of DM, overall survival (OS) 
and recurrence free survival (RFS) did not differ between the groups. We found a statistical 
significant reduction of post-operative complications in SRT-delay compared to SRT (OR 0·61 [95% 
CI 0·45–0·83] p=0·001).  
Paper II. The aim this study was to evaluate the post-operative complications in relation to the exact 
overall treatment time (OTT). Patients were categorized according to OTT and fractionation. 
Patients that received 5 Gy x 5 were divided into four groups; Group A: 7 days, B: 8-13 days, C: 5-7 
weeks, D: 8-13 weeks. Patients that received 2 Gy x 25 were divided in two groups; Group E: 9-11 
weeks and F: 12-14 weeks. Main outcome was post-operative complications defined as any-, surgical- 
or infectious complication. Adjusted odds ratios (any complication) were; A vs. B OR (95 % CI); 
0.72 (0.40-1.32) p=0.289, C vs. B 0.50 (0.30-0.84) p=0.009, and D vs. B 0.39 (0.23-0.65) p<0.001. 
There were no statistical significant differences between group E and F. 
Paper III. In this study, all available histopathology slides from the resected tumours have been 
reassessed by one pathologist. Tumour regression was the main outcome and secondary outcomes 
were histopathological characteristics and the correlation between tumour response and survival. 
Patients randomised to SRT-delay showed more tumour regression compared to the other arms. A 
complete pathology graded tumour regression (pCR) was seen in about 10 % of the patients after 
SRT-delay. Patients with pCR had improved OS and time to recurrence, compared to patients with 
lower regression grades. Hazard Ratio pCR vs no-pCR: OS: 0.51 (0.26–0.99) p = 0.046, TTR: 0.27 
(0.09–0.86) p = 0.027. 
Paper IV. Long-term follow up of the Stockholm III trial after a minimum follow-up of 5 
years. The endpoints from paper I were analysed. The incidence of LR was 11 of 357 (3,1 %), 13 of 
355 (3,7) %, 7 of 128 (5,5%) in SRT, SRT-delay and LRT-delay. Incidence of DM was 88 of 257 
(24,7%), 82 of 355 (23,1%), 38 of 128 (29,7%). The median OS was 8.14 (7.23-9.98), 10.18 
(8.45-11.68) 10,53 (6.95-11.34) years in SRT, SRT-delay and LRT-delay without statistical 
differences between the groups, log-rank SRT vs. SRT-delay p=0.162 (short course RT 
comparison), SRT vs. LRT-delay p=0.738 (three armed randomisation).  
In conclusion, we found no statistical differences between the arms regarding oncological 
outcomes (LR, DM, OS, RFS). SRT-delay is an alternative with less post-operative complications 
and higher possibility of pCR compared to SRT. LRT-delay demands more RT-resources without 
any other obvious gain.  
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BACKGROUND│1 
Background 
Epidemiology 
Colorectal cancer (CRC) is the second most common cancer in Sweden in both females and males 
and more than 6000 individuals are diagnosed yearly. Rectal cancer (RC) accounts for about one 
third of the cases corresponding to an incidence of about 19.9 and 27.6 / 100 000 persons in 
women and men respectively. The mortality rate has been stable around 5 and 10 /100 000 persons 
in women and men respectively.1,2 Globally, it is the third most common cancer after bron-
chus/lung- and breast cancer. Yearly about 1.7 million new cases are diagnosed worldwide. There 
is a variation in incidence depending on sociodemographic index (SDI). Countries with the highest 
SDI has the highest incidence in contrast to countries in the lowest SDI-quintile, where CRC is 
the eighth most common cancer.3 Data from the GLOBOCAN database have been analysed in 
terms of CRC by Arnold et al.4 Globally three different patterns of incidence and mortality were 
observed. Increases in both mortality and incidence were seen in some countries in Eastern 
Europe, Latin America and Asia. In the Northern European countries, UK, Netherlands, Canada 
and a few more countries there was an increase in incidence but a decline in mortality. A third 
group was countries with a decline in both incidence and mortality such as the US, New 
Zeeland, Australia and Iceland. The different patterns are highly correlated to the human 
development index (HDI), see Figure 1 for details. In Sweden, the incidence and mortality have 
been more or less stable for the last 15 years.2 The reduction of mortality may in some countries 
be an effect of the implementation of guidelines and thereby optimising the treatment for CRC. 
The introduction of screening programs might explain the decline in some countries. The 
increase in incidence is probably related to changes in life style factors in countries with lower 
HDI. 
Risk factors 
It has been proposed that the attributable risk of dietary factors on CRC are almost 50 %.5 Many 
life style factors and dietary habits have been explored with the ambition to explain the causes of 
CRC.6 Smoking is clearly associated with CRC and the correlation might be stronger in rectal than 
Figure 1. Age-standardised incidence and mortality rate of colorectal cancer by human development index (HDI). Reprint with 
permission from Arnold et al.4 
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in colon cancer.7,8 Both high weight and high Body Mass Index (BMI) are linked to risk for CRC.9 
Alcohol consumption show a dose-response relationship in the aspect of developing both 
colorectal adenomas and CRC.10,11 High intake of red or processed meat is significantly associated 
with a higher risk of CRC. However, the association seems stronger for cancers in the colon rather 
than in the rectum.12,13 High intake of milk products have shown to be protective, but the 
association is weak and it is not clear which nutrients, i.e lactose, vitamin D or dietary calcium, that 
would be responsible for the risk reduction.12,14-16 Other protective factors might be high intake of 
dietary fibres, although the ideal source of fibre is not determined.17 High physical activity has been 
shown to reduce the risk for colon cancer, but the effect on RC is not as convincing.18,19 Further, 
a meta-analysis concluded that physical activity results in better CRC related survival. However, 
the included studies had different definitions of physical activity and the optimal cut-off level was 
not determined.20 
Inflammatory bowel disease, both Crohn’s and ulcerative colitis are well known risk factors for 
developing CRC.21,22 A considerably increased risk for gastrointestinal (GI) cancer is seen in 
patients with onset of disease in childhood. Hazard ratio (HR) (95 % confidence interval (CI)) 18 
(14.4-22.7).23 
Hereditary risk 
In about 5% of the patients with CRC, a specific genetic mutation is found. However, for 
individual patients with inherited tumour syndromes, there is a substantial risk of developing 
CRC with a life time probability of 50-100%, depending on type of syndrome.24 The hereditary CRC 
syndromes are divided into polyposis or nonpolyposis syndromes based on the number and 
histology of polyps in the bowel. Familial adenomatous polyposis (FAP) is recognized by a 
large amount of polyps throughout the colon, with a high risk of CRC. Up to 1/3 of FAP 
cases are de novo mutations, otherwise FAP is an autosomal dominant inherited mutation with 
a 100 % penetration by the age of 40.25 Other polyposis syndromes include Peutz-Jegher and 
juvenile polyposis, among others. The main proportion of nonpolyposis CRC are patients with 
Lynch syndrome with a life time risk of CRC of about 50 %. 
Swedish ColoRectal Cancer Registry 
In 1995 the Swedish Rectal Cancer Registry was founded. After a merge with the Swedish 
Colon Cancer Registry in 2007 there has been one registry, the Swedish ColoRectal Cancer Registry 
(SCRCR). All registry data are recorded prospectively by the surgeons, pathologists and 
oncologists responsible for the patient. All CRC are reported, except for autopsy findings. 
The national coverage is estimated to be >97 %.26 Recorded data include basic patient 
characteristics, preoperative tumour data (since 2007), neo-adjuvant therapy, type of 
surgery, post-operative complications, pathology report and adjuvant treatment. Recurrence 
data and long-term toxicity are reported at one, three and five years after surgery. Data on 
survival are linked to the Swedish population registry. The SCRCR has been validated at several 
times.26-28 In the latest validation, the agreement between registry data and medical charts was 90 
% on average.28 The post-operative course was the least valid parameter with only about 63 % 
agreement. Although, high ratio of correct values, some variables have a large amount of 
missing data, especially preoperative staging. 
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Anatomy 
The rectum is the most distal part of gastrointestinal tract. The dentate line demarks the transition 
of columnar glandular epithelium of the bowel to the squamous epithelium of the anal canal. At 
present, cancers with a distal extension < 15 cm from the anal verge (measured by rigid 
sigmoidoscopy) are considered as RC according to the European Society of Medical Oncology 
(ESMO)-guidelines and the Swedish national care programme.29,30 The definition has somewhat 
varied over time and potential important differences exist in the inclusion criteria in influential 
trials, both regarding height in cm and measurement technique. For instance, in the Swedish Rectal 
Cancer Trial the definition was “below the sacral promontory, as shown on lateral projection on 
barium enema”.31 The Dutch TME trial and the German CAO/ARO/AIO-04 trial included 
patients with tumours with a height limit of < 12 cm, but another German trial had the cut-off 
level at <  16 cm.32-34 A more anatomical definition is used by the American Joint Committee on 
Cancer (AJCC) which states “Approximately 12 cm in length, the rectum extends from the fusion 
of the taenia to the puborectalis ring.35 One problem of using a fixed cm measurements is that the 
individual length and distance from anal verge to anatomical landmarks varies in relation to BMI, 
age, gender and weight.36 The rectum lies infra peritoneally, with the lowest peritoneal reflection in 
the anterior aspect, the pouch of Douglas. Below this level, between the rectum and the posterior 
vaginal wall or prostate in female and male respectively the Denonvilliers’ fascia is found. The 
exact embryonal origin is undetermined and the optimal dissection plane in this area is also 
somewhat debated. If dissection is performed anterior of the fascia there is a risk of nerve injury, 
but it is of uttermost importance to dissect in front of the perirectal fascia.37 The rectum is covered 
with a fatty envelope containing vessels for arterial supply, venous and lymphatic drainage together 
with lymph nodes. This is today known as the mesorectum. A term introduced by Heald when he 
introduced the “total mesorectal excision” (TME) in 1982.38 Whether the mesorectum really is a 
true mesentery of the rectum or not has been questioned, but the surgical terminology of a 
mesorectum remains unthreatened.39 The mesorectum is covered with the endopelvic fascia or the 
mesorectal fascia (MRF).   
The main arterial blood supply comes from the superior rectal artery (SRA) – the end branch of 
the inferior mesenteric artery (IMA), and the inferior rectal artery (IRA) –branch from the internal 
iliac arteries. With highly reported differences in frequency (12-97 %) the middle rectal artery 
(MRA) – which arises directly from the internal iliac arteries, also supplies the rectum.40 Lymphatic 
drainage follows the arteries. Understanding of lymphatic drainage is of most importance since 
cancer spread through lymph nodes and vessels is a major cause of treatment failure in RC.41  
Clinical presentation 
The median age to be diagnosed with RC is about 70 years. Less than 5 % of patients are younger 
than 50 years.42 However, recent data suggests that CRC in the younger population is increasing 
around the world.43,44 Initial symptoms of include local signs in form of rectal bleeding or mucinous 
discharge and/or pain, change of stool habits, or faecal incontinence. General symptoms may 
include abdominal pain or discomfort, weight loss, fatigue and anaemia. In case of distant 
metastases other adjacent symptoms may occur. In a modern European patient cohort, about 22-
26 per cent of patients have metastatic disease at time of diagnosis.45 Acute symptoms at time of 
diagnosis, such as bowel obstruction or perforation are seen in up to 15 % of patients with RC. 
4│BACKGROUND
The frequency is probably higher in colon cancer. Patients requiring emergency interventions have 
a poorer outcome.46,47 With increasing implementation of screening programs a larger proportions 
of patients will be diagnosed with earlier tumours and with less symptoms.48 
When RC is suspected a digital rectal examination should be performed to assess the size and 
mobility of the tumour, and to describe the relationship to other pelvic structures. A biopsy is 
needed to confirm invasive adenocarcinoma. Although rare, other malignancies might be found 
in the rectum, such as neuroendocrine tumours, sarcomas, lymphomas, melanomas or metastases 
from other organs.49 Anal cancer is a type of squamous cell carcinoma with growth in and around 
the anal canal and can in some cases present as a rectal mass. A rigid sigmoidoscopy should be 
performed to further assess the tumour and to measure the distance from the anal verge and to 
classify the tumour in to low (0-5 cm), middle (6-10 cm) or high (11-15 cm).29 This subgrouping 
guides the further decisions regarding treatment. In addition, a complete investigation of the colon 
with colonoscopy or CT colonoscopy is warranted since synchronous tumours are reported in 5- 
10 %, a missed second cancer requires additional surgery and might affect long-term outcomes.50 
Table 1 TNM-classification of colorectal cancer, 8th edition. 
Tumour  
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no 
extension through muscularis mucosae) 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria into the pericolorectal tissues 
T3a Minimal invasion: <1 mm beyond the borders of the muscularis propria 
T3b Slight invasion: 1-5 mm beyond the borders of the muscularis propria 
T3c Moderate invasion: >5-15 mm beyond the borders of the muscularis propria 
T3d Extensive invasion: >15 mm beyond the borders of the muscularis propria 
T4 Tumour penetrates the visceral peritoneum and/or directly invades other organs or 
structures  
T4a  Tumour penetrates to the surface of the visceral peritoneum  
T4b  Tumour directly invades or is adherent to other organs or structures 
Lymph nodes
NX Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in 1-3 regional lymph nodes 
N1a  Metastasis in 1 regional lymph node  
N1b  Metastasis in 2-3 regional lymph nodes  
N1c  Tumour deposit(s) in the subserosa, mesentery or nonperitonealized pericolic or 
perirectal tissues without regional nodal metastasis 
N2  Metastasis in ≥4 regional lymph nodes  
N2a  Metastasis in 4-6 regional lymph nodes 
N2b  Metastasis in ≥7 regional lymph nodes 
Metastases 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis  
M1  Distant metastasis  
M1a Metastasis confined to one organ or site 
M1b  Metastases in more than organ/site or peritoneum 
Adapted from from Amin et al.35 
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Staging of rectal cancer 
RC should be staged according to the TNM classification system, T-tumour, N-node and M-me-
tastases. Staging is performed preoperatively to be able to choose the optimal treatment for the 
individual patient. The preoperative staging is summarized in a “clinical stage” indicated with c in 
front of TNM stage, i.e cT2N1M0. Post-operative (pathology graded) stage has a strong prognostic 
value and is used for risk stratification and to guide decisions on adjuvant treatment. The pathology 
stage is indicated with the prefix p, i.e pT3bN1M0. If neo-adjuvant therapy has been given, an y is 
used in front of the p. The TNM system is revised by AJCC and Union for International Cancer 
Control. The 8th edition was released in December 2016.35 The 7th edition is recommended in 
Swedish National Programme. The differences between the 7th and 8th editions are small regarding 
RC.51 Important changes include; in situ tumours (Tis) are referred to as intramucosal 
adenocarcinoma, T and N categories have not changed but isolated tumour cells <20 cells in lymph 
nodes should be considered as N0, and micro metastases (>20 cells or size of >0.2 < 2 mm) are 
N1.52 The TNM-system is designed for postoperative staging, but are used also for preoperative 
cStage. However, no preoperative method can categorize patients with the same high resolution 
as the histopathological examination (Table 1). 
T‐stage 
The invasion depth of the cancer tumour into the bowel wall decides the T-stage. The patient’s 
prognosis is worse with higher T-stage.53,54 In Figure 2, T1 to T3 are illustrated. T4 tumours are 
invading through the bowel wall and can be subtyped in T4a – only growth through the serosa, 
and T4b, growth into other organs. 
N‐stage 
The number of metastatic lymph nodes is the base for the N-classification. Only regional lymph 
nodes are considered when deciding N-stage, metastatic nodes in other regions are seen as distance 
metastases. In RC, the regional nodes are perirectal, along the sigmoid/inferior mesenteric arteries, 
in the pre- and lateral sacral spaces, along the internal iliac artery, around the sacral promontory, 
and along the rectal arteries. Tumour deposits are foci of metastatic disease in the perirectal fat. 
They may represent discontinuous spread or venous invasion with extravascular spread or a 
metastatic lymph node destroyed beyond all recognition by tumour growth. These deposits are 
classified as N-stage disease (N1c). 
M‐stage 
The M-stage describes the presence of distant spread of the tumour to other organs, peritoneal 
cavity or extra regional lymph nodes. 
Preoperative staging  
The preoperative investigations focus at three areas. The local growth of the tumour, the nodal 
spread and metastatic situation.  
Tumour and nodal assessment 
In the Western world magnetic resonance imaging (MRI) assessment of RC is mandatory and the 
treatment decisions are highly affected by the result. The use of MRI has been introduced as a 
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standard of care since the early 2000s, when it could be shown that the MRI-staging had a high 
correlation with the pathology assessment.55 MRI can accurately stage both T- and N-stage. 
Nodal assessment and the subsequent staging is based on the number of nodes suspicious for 
malignancy. The shape, rather than the size, combined with irregular borders and a mixed signal 
intensity is indicative of metastatic nodes.56 Other important clinical findings that can be assessed 
are the relationship to the MRF, which corresponds to the future resection plane, or the 
circumferential resection margin (CRM). A positive or threatened mri-MRF is considered in most 
guidelines to be an indication of chemoradiotherapy (CRT). Extramural vein invasion (EMVI) 
has been stressed to be a significant risk factor by the Royal Marsden group. EMVI+ patients 
had odds ratio (OR) (95 % CI) 5.68 (3.75-8.61) and 3.91 (2.61-5.86) of having synchronous or 
developing distant metastases after surgery, respectively.57. MRI have been considered to have a 
higher predictive value regarding CRM and T-stage compared to N-stage in a review and meta-
analysis from 2012.58 
Metastases 
Computed tomography (CT) of the thorax and abdomen, including the pelvis is used mainly to 
detect metastatic disease. The possibility of detecting hepatic metastases is good, with 
high sensitivity and specificity using CT-scan.59 A focused MRI of the liver might be used when 
lesions cannot be categorized by CT-scan, due to the higher specificity.60 Pulmonary metastases 
are harder to diagnose, and figures of 4-42 % of pulmonary lesions cannot get a final diagnosis, 
and only 25 % of lesions found on chest CT turn out to be metastases.61,62 
Post-operative staging 
The pathology assessment of the surgical specimen is the foundation of the postoperative staging. 
The (y)p Stage, based on T- and N- stages is presented in Table 2. Other parameters that should 
be reported are tumour infiltration in vessels, nerves, the distance to the CRM and differentiation 
of the tumour.  
Figure 2. Illustration of tumour invasion depth (T) stage 1-3 according to international TNM-classification. Reprint (modified) 
with permission from AJCC cancer staging atlas.51
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Positive venous invasion, V0/1, and especially extramural 
venous invasion, EMVI +/- is associated with poorer 
outcomes regarding survival and distant metastases, and 
patients with the latter have been reported to have similar 
outcomes as ypStage III tumours.63 Tumour infiltration 
of the lymphatic vessels, L 0/1, might predict future 
lymph node metastases, but in RC the association is 
weaker than in colon cancer.64 Perineural invasion (PN) 
has been defined as tumour growth in, around and 
through peripheral nerves.65 The definition is however 
somewhat debated and subsequently the diagnosis might 
not be totally comparable between studies. Albeit, PN+ 
has been reported as an independent bad prognostic 
factor, also in patients who had neo adjuvant therapy.66,67 
Resection margins 
An involvement of the CRM after RC surgery is a strong risk factor for local recurrence (LR). 
Quirke et al. analysed 52 specimens and found that in patients with involved CRM the LR 
incidence was 85 %.68 This association has later been confirmed in other studies.69 Today, a 
positive CRM is often defined as a margin of < 1 mm. An assessment of the quality of the TME-
specimen in regards of the MRF has been proposed to be a part of the standard pathology 
report. By categorizing the plane of surgery into three levels based on a macroscopic evaluation 
Quirke et al. showed that the quality of surgery predicts LR.70 Further, an incomplete TME is also 
associated with higher rates of distant metastases (DM).71 Spread of RC proximal and distally is 
also possible, the proximal resection margin is seldom a problem since the bowel is resected at 
least at the level of the arterial ligation. The distal margin should be at least 1-2 cm in low – 
middle RCs under the condition that a complete TME is performed. In high RC, a partial TME 
might be performed and then 5 cm margin is required.72,73 
Grading of differentiation 
It has been known for decades that oncological outcomes are associated with the grade of 
differentiation in CRC.74-76 Previous commonly used classifications included well-moderate-poor 
differentiation. Due to high interobserver variability a two tier classification was recommended 
from the WHO, high-grade- vs- low-grade cancer with a cut off level at 50 % glandular 
formations.77,78 Other differentiation patterns include the mucinous type, defined by > 50% 
extracellular mucin. The signet ring cell adenocarcinoma is rare (<1 % of RC) and has a poorer 
prognosis.79 Finally, an extremely rare type is the medullary cancer with an estimated incidence of 
5-8 cases / 10 00 CRC.80 
Residual tumour 
Classification of the residual tumour status (R) is important since it strongly correlates with LR, 
DM and survival.81 The classification is R0 – no residual tumour, R1 – Microscopic residual 
tumour, R 2 – Macroscopic residual tumour. 
Table 2. TNM-stage 
Characteristic Stage
Tis N0 M0 0 
T1-2 N0 M0  I 
T3 N0 M0  IIA 
T4a N0 M0  IIB
T4b N0 M0 IIC 
T1-2 N1 M0 / T1 N2a M0 IIIA
T3-4a N1 M0 / T2-3 N2a 
M0 / T1-2 N2b M0  
IIIB 
T4a N2a M0 / T3-4a N2b M0 / 
T4b N1-2 M0  
IIIC
Any T Any N M1a  IVA 
Any T Any N M1b IVB
Adapted from Amin et al.35
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Tumour regression grading 
There are several different grading systems for assessing tumour regression after neo-adjuvant 
(C)RT in patients with RC, (Table 3). They have been adapted and modified from a system initially 
described for upper GI-cancers. Mandard et. al. found that the tumour regression grade (TRG) 
was a significant predictor of disease free survival (DFS) in in 93 patients with oesophageal cancer. 
82 Dworak et. al. proposed a 5 tier system in RC, which has been commonly used.83 Ryan et. al 
introduced a three-tier system. This grading system was considered to be more reproducible than 
the 5- tier system, advocated by others.84 Vecchio et. al found that TRG according to Mandard 
predicted overall survival (OS) and DFS and the “TRG-system” was used by some authors.85 Other 
systems, such as the 3 tier Rectal Cancer Regression Grade and its modified version (m-RCRG) 
system have also been used.86,87 AJCC later adopted a 4-tier system.35 In one comparison, none of 
the commonly used regression grading systems predicts recurrence free survival (RFS) or OS better 
than the standard ypStage.88 One major issue with all the regression grading systems is that the 
interobserver variation is high. It has been reported -scores of 0.72-0.74 for the TRG and 
mRCRG systems between two observers.86 In other settings the -scores for Mandard, Dworak 
and mRCRG were 0.28, 0.35 and 0.38 respectively.89  
Downstaging of the tumour and high grade regression are associated with improved oncological 
outcomes in many series but outcomes after a near-complete response are conflicting.90-95 Another 
issue that most of the regression grading systems only focuses on the downstaging of the tumour 
and no formal assessment of metastatic lymph-nodes is done. This has been suggested to be im-
portant by some authors that found lymph node regression grade to be a prognostic determinant. 
96 Other studies found that a pathologically grade complete response (pCR) only is beneficial in 
patients with cStage III disease. 97 
Table 3 Tumour regression grading systems
Dworak83 AJCC35 Mandard82 Ryan84 
No regression No regression (TRG 0) - Absence of 
regressive 
change 
(TRG 5) 
- 
Minimal Dominant tumour 
mass with obvious 
fibrosis and/or 
vasculopathy (TRG 1) 
Minimal or no 
tumour cells killed 
(TRG 3: poor 
response) 
Residual cancer 
outgrowing 
fibrosis 
(TRG 4) 
Significant fibrosis 
outgrown by cancer, or 
no fibrosis with extensive 
residual cancer (TRG 3) 
Moderate Dominantly fibrotic 
changes with few 
tumour cells or groups 
(TRG 2) 
Residual cancer 
outgrown by fibrosis 
(TRG 2: minimal 
response) 
Fibrosis 
outgrowing 
residual cancer 
(TRG 3) 
Residual cancer outgrown 
by fibrosis (TRG 2) 
Near complete Very few tumour cells 
in fibrotic tissue with 
or without mucous 
substance (TRG 3) 
Single or small 
groups of tumour 
cells (TRG 1: 
moderate response) 
Rare residual 
cancer cells 
(TRG 2) 
- 
Complete No tumour cells, only 
fibrosis (TRG 4) 
No viable cancer 
cells  
(TRG 0) 
No residual 
cancer 
 (TRG 1) 
No viable cancer cells, or 
single cells, or small 
groups of cancer cells 
(TRG 1) 
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MDT-conference
The multidisciplinary team conference (MDT) gathers all specialties involved in the care of the 
patient with RC. Typically, team members are colorectal surgeons, radiologists, oncologist, 
pathologists and specialized nurses. Patients are often discussed both pre- and postoperatively, or 
during treatment, i.e if an evaluating MRI is performed during neo-adjuvant treatment. The aim of 
the MDT-conference is to improve the care and outcomes of the patients. With increasing 
knowledge of treatments of RC, it is impossible for the single clinician to be up to date in all 
subspecialties in the chain of care. In Sweden it is mandatory according to the National guidelines 
to discuss patients with CRC in a MDT-conference. The introduction of MDT-boards has 
probably resulted in better preoperative staging and better adherence to guidelines. No improved 
hard outcomes, such as OS or DFS have been proven in studies. However, patients discussed at 
MDT boards had more MRI performed, more complete staging and fewer CRM-positive 
resections.98-100
Stratified neo-adjuvant treatment 
Treatment recommendations or decisions from the MDT-board are in many cases based on a 
risk stratification from the perspective of LR. This is natural since LR historically has been the 
main issue in patients with RC. In Sweden, for the last two decades patients’ tumours have been 
stratified in to three risk groups, the good, the bad and the ugly.101 Still today, this is the basis for 
the selection of preoperative treatment, (Figure 3). Some extensions have been made, especially 
regarding patients with mriEMVI+, that are considered to be at high risk and should be given 
radiotherapy (RT).102 In the recent ESMO-guidelines tumours are categorized in five groups 
instead, RT is reserved for patients with “bad”- tumours or worse, under the condition that LR 
rates are <5 %.29 In Japan CRT is reserved for low-medium tumours deemed unresectable, 
otherwise lateral node dissection is more commonly used.103 In the US, the NCCN-guideline 
strongly advocate CRT to all patients except T1-T2 N0 tumours.104 
Figure 3. MRI-based stratification of neo-adjuvant treatment according to Blomqvist & Glimelius. Reprint with permission.101
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Radiotherapy 
The definition of radiation is the transmission of energy in the form of waves or particles through 
space or in a medium. Particles includes protons, electrons, ions (like carbon) and pions. In clinical 
RT, electromagnetic radiation is used. The carrier of the radiation is the photon, which not is 
considered a particle. Radiation can be either ionizing or non-ionizing. The energy level of the 
particles decides the effect. Ionizing radiation has the ability (enough energy) to break chemical 
bonds and ionize atoms and molecule, directly or indirect. The effect on human tissue depends on 
the type of radiation and exposed tissue. The linear energy transfer (LET) is the amount of energy 
a particle deposits in local ionizations per unit path length (measured in keV/µm), i.e the amount 
of damage in the track of the particle. The biological effect in tissue is naturally a result of the LET 
level. High LET radiation types are neutrons, protons and heavy charged particles. Low LET types 
are for instance X-ray and gamma radiation. The absorbed radiation dose is expressed in Gray (Gy) 
which is equal to joules/kg.105 
The energy deposited in the tissue leads to ionization, with the subsequent conversion of free 
radicals from atoms and molecules. The radiation induces several molecular signalling pathways in 
the cells and tissues including DNA-repair, cell cycle arrest, apoptosis, proliferation, inflammation 
and fibrosis. These steps are the response to the RT and the effect is that irradiated cells are killed 
and replaced with scar tissue The effect may be direct or indirect. Ionizing effect on DNA or cell 
membrane will lead to a direct effect. Other effects include the inability of mitosis. The effect of 
RT is highest when the cell is in the proliferation cycle, especially during mitosis. Thus, tissues with 
high proliferation rate are more sensitive to RT. Malignant tumours are characterized by a rapid 
growth, and are theoretically more sensitive to RT. 
Cell death is usually defined as loss of “clonogenic” capability, i.e the ability to reproduce. Cells 
with damaged DNA may however divide and grow for some time before the cell division capability 
stops. There are different patterns of cell death after RT. Necrosis, where the death is uncontrolled 
and highly inflammatory. When cells are programmed to die it is called apoptosis and the cells 
breaks down in a controlled manner without inducing any inflammation. Certain radiosensitive 
cancer forms respond with a lot of apoptosis, e.g. lymphomas and neuroblastomas. Another form 
of cell death is the “mitotic catastrophe” which occurs when cells cannot segregate their 
chromosomes during mitosis. The DNA-damage is not lethal until mitosis takes place, and this is 
one reason why tumour regression sometimes takes several days or weeks after end of RT. 
Fractionation of RT is in most cases biologically superior to single-fraction RT. Four R’s have 
classically been used to describe the biology of fractionation. Repair – normal tissue must repair 
the DNA-damage, which takes time. Reoxygenation – the tumours need to re-oxygenate, central 
parts of the tumour might have impaired blood flow. Redistribution – the cells must have time to 
move forward in the cell cycle in order for RT to have the best effect. Repopulation –Cells 
repopulation varies during RT, a kick-off time is often described at a certain point when 
repopulations accelerates. Also normal tissues must have time to repopulate. A fifth R can also be 
used, “Radio sensitivity”. A common model to describe cell death clinically is the Linear-Quadratic 
model.  
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𝑆𝐹஽ ൌ  𝑒ିሺఈ஽ାఉ஽మሻ 
SF = surviving fraction, D = dose, 𝛼 = the unrepairable damage, independent of fraction and dose 
rate. 𝛽 ൌ the repairable damage, dependent on dose and fractionation. 
The α/β ratio differs between tissues. Low ratio tissues have high abilities to repair, in contrast to 
tissues with low repair abilities (high α/β ratio). The former is relatively resistant to small fractions 
and the latter is sensitive to small fractions, (Figure 4 A). The knowledge of different ratios is 
important to decide the optimal fractionation. Typical high α/β tissues are most tumours. Most 
normal tissues have a low α/β ratio. With the knowledge of α and β values the biologically effective 
dose (BED) can be calculated and it’s possible to compare different RT-schedules. It is also pos-
sible to estimate what doses that are accepted in tissues and organs surrounding the tumour or 
target. The difference between the “tumour control probability” (TCP) and the normal tissue 
complication probability (NTCP) can be referred to as a therapeutic window, (Figure 4B). Based 
on the reason above, it is logic to fractionate RT. Tumours take more damage than surrounding 
cells. Different tumours have different ratios, breast and prostate cancer are considered low α/β 
tumours. The α/β ratio and BED of different RT-schedules are in RC somewhat debated. 106. 
Analysing retrospective data have proven to be difficult due to different fractionation schedules 
and overall treatment time (OTT). It has been suggested that RC has values closer to prostate 
cancer which also is a adenocarcinoma.107 An α/β of 10 Gy has been used, initially derived from 
head neck cancers (squamous cell carcinoma).108,109 One study concluded that RC probably has a 
“moderately low α/β ratio”.110  
Radiotherapy in rectal cancer 
Today, the aim of RT in RC is to reduce the number of LR. During the years, many RT regimens 
with different schedules of fractionation have been used. At present, two different courses are 
dominating. Either a conventionally fractionated long-course of 1.8-2 Gy x 25-28 with delayed 
Figure 4. Relationship between cell death and dose. A) Surviving fraction of cells in three hypothetical tissues with different α/β 
ratios. B) The relationship between tumour control and normal tissue. NTCP-normal tissue complication probability, TCP – 
tumour control probability. 
12│BACKGROUND
surgery (LRT-delay), most often combined with chemotherapy (CRT). An alternative is a short 
course, 5 Gy x 5 (SRT). In the European countries, neo-adjuvant RT is most commonly used. 
More than 60 % of Swedish patients with RC were treated with neo-adjuvant RT in 2015, with a 
registered national variation of 26-92 %.111 The use of RT also varies around the globe, and even 
in the Nordic countries.112,113 In the US neo-adjuvant CRT is the dominant therapy.114 Although 
widely used and well-studied, the optimal fractionation or timing of surgery is not agreed upon.115 
Fractionation and timing of surgery 
Attempts to treat or palliate patients with RC with irradiating radium sources trace back at least to 
the early 1900s with reports on tumour regression and turning inresectable tumours available for 
surgery.116,117 Initial experiences from RT in squamous cell carcinomas were explored in RC. 
Initially, adenocarcinomas of the rectum were considered to be radio resistant. Later it was found 
that the tumour regression takes longer time and a complete regression can occur up to 3 months 
after RT.118  
The first randomised trials that could show fewer LR after preoperative RT enrolled patients in 
the late 1970s and early -80s.119,120 The rationale of using preoperative RT instead of 
postoperatively is based on results from several trials. The Uppsala trial randomly assigned 
patients to preoperative SRT or postoperative 2 Gy x 30 and it was stated that preoperative RT 
was better tolerated and more effective.121-123 Later, the Stockholm I trial showed a reduction of 
LR from 28% to 14 % after pre-operative short course RT (SRT) and immediate surgery, 
however at the price of an increased postoperative mortality.124 The radiation was delivered in a 
suboptimal way and with a large target area, compared with current guidelines.30 The Swedish 
Rectal Cancer Trial and the Stockholm II trial showed, apart from a decrease in LR, a survival 
benefit for patients that received preoperative SRT compared surgery alone.31,125,126 The Dutch 
TME-trial randomised patients between preoperative SRT and surgery within one week or 
surgery alone, simultaneously as the TME-concept was introduced and formally trained. The 
cumulative incidence of LR was 11 % in the non-irradiated group and 5% after pre-op RT. 
Thereby confirming that RT approximately halves the proprtion of LR, even from low numbers 
after optimised surgical technique.127. 
In a systematic overview published in 2001 it was concluded that preoperative RT reduces the 
risk of LR and death from RC.128 However, one potential disadvantage with pre-operative 
treatment is that all patients are treated. When RT is delivered post-operatively instead, only 
patients considered to be at high risk for LR can be offered treatment. In the MRC-CR07 trial 
patients were randomised to preoperative SRT or to selective post-operative CRT if the 
circumferential resection margin was involved. The results, after a median follow up of 4 years 
were that the preoperative SRT group had a 61 % reduction of LR, an improvement of DFS but 
not in OS. HR OS 0.91 (0.73-1.13), p=0.40.129 A German trial concluded that preoperative CRT 
gave less toxicity and better local control compared to postoperative CRT.33 After a follow up of 
minimum 11 years of the same trial, LR rates were still significantly lower after preoperative CRT, 
7.1 % vs 10.1 %, but no differences in distant failure or DFS.130  
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LRT‐delay and CRT 
LRT-delay has been used for several years. Three trials have proven better local control with the 
addition of concomitant chemotherapy, compared to RT alone, but without survival benefit, 
except for locally advanced cancers.131-133 Based on these trials, LRT-delay is practically abandoned 
in favour of CRT. 5-flourouracil or per oral capecetabine is often used as the adjuvant chemo and 
is likely equal, but capecetabine is more convenient.134 An additional boost of 5.4 Gy delivered in 
3 fractions may be used in some settings, with the ambition to assure R0 resection.135 The 
addition of chemotherapy increases the treatment toxicity, and could even influence the mortality. 
In one meta-analysis the HR for toxicity related mortality was HR 2.86 (0.99-8.26).136 The 
addition of further cytotoxic agents such as oxaliplatin have been explored in several trials, but 
without convincing beneficial results. Two meta-analyses concluded decreased risk for DM but 
without any improvement of DFS or OS.137,138  
Short course radiotherapy 
The SRT was introduced as an option to postoperative conventionally fractionated LRT, with 
possible practical gains.139 The standard SRT-course is 5 Gy x 5 delivered Mon-Fri and surgery 
early in the following week. The SRT-course has been explored in several trials, mentioned above. 
The effect on LR has also been confirmed outside the randomised trials and there is a tendency of 
improved survival in low tumours.140 Later, two trials have randomised patients to CRT or SRT in 
patients with T3/T4 resectable cancers, with similar study protocols. Both the trials concluded that 
SRT with immediate surgery are not significantly different from CRT with respect of DFS, OS or 
rate of LR, but with more acute adverse events in the CRT group.141-143  
The optimal time interval within the first week is however debated. In a subgroup analysis from 
the Dutch TME-trial elderly patients (>75 years) were found to have worse survival if operated on 
4-7 days after last RT, compared to having surgery performed 0-3 days after RT.144 In part, this 
might be explained by an impaired leukocyte response, or even a drop in leukocyte count, seen 
around 5 days after the last given RT fraction. This was found in retrospective studies of the 
Stockholm I-II trials, and also in an interim analysis of the Stockholm III.145,146 Other studies 
found a correlation between overall post-operative complications and low leukocyte ratio in the 
2 first days after surgery, in irradiated patients.147 However, a large Dutch registry based study 
analysed 2131 patients and concluded that there was a higher probability of anastomotic leaks 
(AL) in patients having surgery 0-3 days compared to 4-14 days after end of RT (10.1% vs 7.2 %, 
p=0.018).148 In conclusion, the exact timing of surgery seems to matter in the early period, 
depending on the outcomes of interest. 
SRT‐delay 
SRT-delay, 5x5 Gy and surgery 4-8 weeks after the last given fraction, was first introduced in 
patients not fit for CRT and the feasibility and safety have been evaluated in retrospective 
studies.149-151 RT induced toxicity was seen in about 5-6 %, and the treatment option has been 
considered tolerable. Few prospective trials have explored SRT-delay, except for the Stockholm 
III trial. An interim analysis presented the results on feasibility in 2010.152 The patient inclusion 
continued and the results after, a minimum follow up of two years, were presented in 2017, as a 
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part of this doctoral thesis. The oncologic results were considered similar but with reduced number 
of postoperative complications when delaying surgery for 4-8 weeks after SRT.153 
Other studies exploring a delay after SRT include a retrospective study by Veenhof et al. who 
studied 108 patients, with surgery < 2 weeks or with a delay 6-8 weeks after RT. No statistical 
differences regarding oncological outcomes were found.154 A small polish trial randomised patients 
between SRT with immediate surgery or a delay for 4-5 weeks. Tumour regression was seen after 
delayed surgery and patients with tumour regression had an improved 5-year OS.155 A phase II 
trial concluded that the SRT-delay regimen was feasible and with acceptable toxicity.156 A Japanese 
study compared outcomes from two centres that used a modified SRT-delay course (2.5 Gy x 2 x 
5, with a concomitant radio sensitizer) or CRT. The results showed no statistical differences in 
RFS, OS or tumour regression.157 A Lithuanian trial randomised 150 patients between SRT-delay 
and CRT. The conclusion was that OS did not differ significantly between the groups. However, 
the DFS was 59.1 % vs 75.1 % (p=0.022) favouring CRT.158 A Turkish group conducted a 
retrospective study on 136 patients with immediate or delayed surgery with improved survival in 
SRT-delay.159 A recent meta-analysis has pooled five of the studies mentioned above and 
concluded that surgery should be delayed for > 4weeks after SRT.160 Notable is that the 
Stockholm III trial contributed with 712 of 1244 patients in the study, and patients in the other 
studies might not be totally comparable. In summary, the use of SRT-delay seems to have 
become an accepted alternative to SRT.161 
Figure 5. Complete tumour regression after seven months demonstrated by barium enema.
Reprint with permission from Cummings et al.118 
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Tumour regression 
RT induces cell death and a possible regression of the irradiated tumour. To achieve a pCR was 
previously considered to be without prognostic value.162,163 Today several studies have found an 
improved survival in patients with pCR. Whether this is a result of the tumour response per se, 
or an effect of a favourable tumour biology is not determined.164,165 The possibility of tumour 
regression and the correlation to the OTT has been known for decades, (Figure 5).118 However, 
considering pCR as an important outcome has more recently gained popularity and the optimal 
waiting time to achieve pCR has not been decided.  
Tumour regression is enhanced by the addition of chemotherapy concomitant to a LRT-
schedule.166 167 In a Swedish, Norwegian and Polish collaboration the pCR rates increased to 16 % 
from 7 % p=0.04, in patients that received LRT and fluorouracil /leucovorin, compared to LRT 
alone.133 In a Dutch registry based study, about 15 % of patients achieved pCR if surgery was 
delayed for 10-11 weeks after CRT, corresponding to an OTT of more than 15 weeks, (Figure 6)168 
A meta-analysis on 13 studies concluded a pCR rate of almost 20 % compared to 14 % if surgery 
was delayed more than 6 –8 weeks.169 Although the relationship graphically seems simple, i.e longer 
waiting time increases the likelihood of pCR, the correlation between pCR and OTT might be 
more complex. In the randomised French GRECCAR-6 trial the proportion of pCR after 7 weeks 
compared to 11 weeks after CRT was not statistically different.170 Retrospective studies have 
found a similar pattern.171 
It was early reported that 
patients receiving SRT had 
visible signs of tumour 
regression if the surgery was 
delayed for at least 10 days.172 
Further studies concluded 
that no tumour regression is 
detectable if surgery is 
performed immediate after 
SRT.173 However, a higher 
grade of tumour regression, 
and even pCR, can be acheived if surgery is delayed at least 4 weeks after SRT.149,174-176 CRT 
induces more pCR than SRT, mainly because of the timing of surgery.142,177 Another, registry 
based, study found that SRT-delay was less likely to induce pCR compared to CRT, adjusted OR 
(95% CI) 0.3 (0.2-0.5).171 
Organ preservation 
The idea of organ preservation in the case of a complete clinical response (cCR), has evolved since 
it was presented from a Brazilian group.178 A review of 15 studies on non-operative management 
after cCR failed to perform a “formal meta-analysis” due to the heterogeneity of the including 
studies. The regrowth rate was found to be 21 % at a mean of 16 months, of which 93% could be 
Figure 6. Cumulative complete response rate in 2203 patients after CRT. Reprint 
with permission from Sloothaak et al.
168
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“surgically salvaged”. A pooled OS was estimated to be 92 %, with a follow up of 23-68 months 
in the included studies. The authors stated that one major problem is that few of the studies had a 
control group and that organ preservation is a possible option only in selected patients.179 A recent 
case series from the US had similar results with about 90 % surgical salvage in patients with 
regrowth, but patients with local regrowth had a worse outcome.180 Other studies have estimated 
the local regrowth to be 21.4 %.181 The concept of “Watch and Wait” has increased in popularity 
and an international database is established. The ambition is to collect a large number of patients 
with prospectively recorded data. Long-term outcomes have been presented and local regrowth 
rate was found to be 25 % of which 97 % were in the bowel wall.182  
Other concepts of organ preserving strategies are local excision or transanal endoscopic 
microsurgery (TEM) instead of TME-surgery in the case of nearly complete responses.  Results 
from the GRECCAR collaboration seems promising, after 5 year follow up.183,184 The ongoing 
STAR-TREC trial is randomising patients with < T3b tumours between standard TME-surgery, 
CRT or SRT followed by TEM-surgery or active surveillance depending on clinical response.185 In 
summary, substantial evidence indicates that an organ preserving approach is safe in many settings. 
Less is known about patients ending up without any signs of regression. These patients will have 
their OTT prolonged, without any obvious gain. At present, this situation is hard to avoid. There 
are no good tools to predict the response after neo-adjuvant (C)RT in RC. Factors such as 
tumour size < 2 cm, low cT- or cN-stage, high radiation dose, delayed surgery, high pre-
treatment CEA-levels and post-treatment tumour size have been identified with some possibility 
to predict pCR.186-188 In the field of MRI, predictive models using multiparametric MRI-
information combined with clinical parameters might be able to identify non-responders.189 
Other groups have identified other MRI-features with the possibility to find good or complete 
response.190,191 However, these are recently published and the findings needs to be confirmed in 
other settings. Further, no genetic profiles have been found with the ability to predict response to 
CRT.192 One interesting finding is that patients with DNA mismatch repair deficiency, or MSI-H 
tumours, might respond well to neo-adjuvant CRT.193 These patients are otherwise known to be 
bad responders to adjuvant flouropyrimidine based chemotherapy. In summary, many attempts 
have been made to identify predictors of pCR. Some of these factors are not of any help in the 
pre-treatment decision phase, such as post-treatment tumour size or delayed surgery. At present, 
no methods are sufficiently specific or sensitive to use for treatment stratification. 
With the ambition of tumour regression and pCR, the time interval after CRT is today often 
prolonged. From the previous standard of 6-8 weeks up to 10-12 weeks. A randomised trial from 
Royal Marsden concluded that there was a higher rate of MRI-measured downstaging and pCR 
after 12 weeks compared to 6 weeks.194 Other studies exploring the optimal interval found that 
there is a larger probability for tumour regression if you wait 14 weeks compared to 9 weeks.195 
Two observational studies from the US with data from the national cancer database analysed 
two cohorts with surgery between 2004-2012.196,197  It was suggested that 8 weeks should be the 
upper limit of delay after CRT. Waiting time beyond 60 days was associated with shorter survival 
and higher rates of positive surgical margin. 
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When delaying surgery, it is important to monitor the patients and the tumour’s response to CRT. 
Otherwise, there is a risk that patients with poor response will follow the same standard course as 
patients with acceptable or excellent response. The evaluation of neo-adjuvant treatment with MRI 
was explored in the MERCURY-trial and it was concluded that TRG can be assessed by MRI and 
even predict survival, OS 27 % vs 72 % in no response vs. good response.198 Other studies have 
concluded similar results.199 However, the overall correlation between MRI- assessed TRG and 
pathology graded TRG has been found to be low in larger materials.200 
Radiation technique 
The RT technique has evolved during the years. In the Swedish national guidelines for RC 
treatment there is an instruction of how the RT should be planned and delivered30. In short, the 
patients are tattooed with a reference point, to be used for field settings and target drawing. RT is 
given with the patient laying down. To avoid the small bowel to come in to irradiation field the 
drawing and treatment can be carried out with a comfortable filled urinary bladder. A dosage CT 
is made for target volume (TV) and dose calculation. Volumes that should be defines are: Gross 
Tumour Volume (GTV). The clinical target volume (CTV) is the primary tumour with 1-2 cm 
margin within the mesorectum, thus including the primary lymph nodes. The nearest “secondary” 
nodes (presacral, along the SRA and the lateral stations) are also included. CTV with the lymph 
nodes are called CTVN The iliacal and inguinal nodes are not included regularly. The planning 
target volume (PTV) includes CTVN plus an additional margin of 0.8-1.3 cm. In the Swedish 
guidelines organs at risk (OAR) are not needed to be defined in SRT. In the more advanced 
tumours (“ugly”), a boost-GTV can be added in areas where surgically resection is expected to be 
troublesome. The CTVN includes the external iliac vessels if the tumour overgrowths the pelvic 
organs, such as the prostate, bladder or vagina. In the very low tumours also inguinal nodes are 
included. In LRT courses, OAR are defined including the bowel bag, bladder, pelvic bones and 
genitals. 
These guidelines are currently being revised and a new version will be released this year. 
Toxicity from radiotherapy 
The beneficial effects of RT, i.e tumour regression and fewer LR comes at the price of acute and 
long-term side effects. Type of acute toxicity depends on dose and irradiated target volume. 
Different grading systems are used to classify the severity of adverse RT events. The European 
Organisation for Research and Treatment of Cancer (EORTC) published a 5-level (0-4) system in 
1995 with specifications for all organ systems.201 Organs in the radiation field are naturally organs 
at risk for toxicity. Other side effects can be effects on circulating white blood cells and bone 
marrow, as previously discussed. The acute RT effects typically subside in a few weeks. In SRT 
little RT toxicity is developed between the time from RT to surgery. Typical symptoms might 
include erythema, diahorrea, urogenital symptoms, neurological complaints or pain. In patients 
with planned short waiting time to surgery these symptoms rarely cause surgery to be delayed or 
requiring hospital admission.202 Acute toxicity symptoms are more frequent in LRT or CRT 
compared to SRT.167 The Stockholm III trial was the first trial to compare acute radiation toxicity 
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between SRT, SRT-delay and LRT-delay. In the arms with a delay to surgery there is time to 
develop toxicity symptoms, and hospitalisation was required in about 6-7% of the patients.153 
The late effects after RT are well known and include faecal incontinence, increased stool 
frequency and urgency, all symptoms are also associated with surgery of RC, but aggravated by 
RT.203 Increased GI-symptoms in general and bowel obstruction in particular have been 
described after RT, compared to non-irradiated patients.204 Patients in the Dutch TME-trial that 
received RT reported impaired quality of life (QoL) even after a follow up of 14 years.205 
However, no impact on general symptoms was seen in the irradiated group. Symptoms of 
urinary dysfunction such as increased frequency, chronic cystitis and incontinence are more 
common in patients after RT.206 In addition, negative effects on sexual function have been 
found in both sexes. In males increased rates of both erectile and ejaculatory problems as well 
as a decreased overall sexual function have been reported. 207 Hypogonadism has recently been 
reported as a potential risk after RT to the pelvis.208 In females,  RT has been l inked to 
dyspareunia, vaginal dryness and overall sexual dysfunction.209. A reduction of sexual desire 
has recently been described as a result of impaired androgen production from the ovaries.210 
Other long-term side effects of RT are pelvic insufficiency fractures (PIF), with chronic pelvic pain 
as cardinal symptom. A Danish case-control study found that 12.2 % of 1100 patients had PIF 
after CRT during a follow up of 36 months. High age and female gender were risk factors.211  
The risk of secondary, RT induced, cancers has been explored in several studies. Patients included 
in two Swedish trials, recruiting patients in the 1980s and -90s were found to have an increased 
risk of a second cancer, RR (95% CI) 1.85 (1.23-2.78).212 A more recent study did not found any 
increased risk for a secondary cancer in irradiated patients, when analysing >13000 patients in the 
SCRCR with follow up of about 20 years.213 In contrast, irradiated patients had a decreased risk of 
prostate cancer. The reduction of prostate cancers was confirmed in other studies, but they also 
found an increased risk for some gynaecological cancers.214-216 The latter study, also found an 
increased risk for lung cancer and lymphoma in irradiated patients.216 
Effect on distant failure? 
In the 1970s and -80s local failure rates after RC surgery were reported to be 12 – 45 % in clinical 
trials, and probably higher in the population.217 After the introduction of TME-surgery together 
with optimised chemotherapy and RT, the introduction of multidisciplinary conferences and other 
actions, the local control is now excellent and is reported to be below 5 % in low-risk tumours. 
Overall 3-year survival has improved from 57 % in 1995 to 62 % in 2012.218 The distant failure in 
form of metastases is however still a major problem and therefore the aim should be to identify 
patients with high risk for distant recurrence. Since the introduction of the concept of good-bad-
ugly, certain patients with cStage II and III disease will receive more aggressive treatment with 
appropriate neo-adjuvant treatment in form of SRT or CRT. Though neo-adjuvant treatment is 
effective on local control, the distant recurrence levels are not affected. This task is addressed by 
the RAPIDO-trial, which is closed for inclusion.219 Patients with high-risk tumours (locally 
advanced – ugly) were randomly assigned to a combination of chemotherapy with high-dose 
capecetabine of 1000mg/m2 and oxaliplatin 130 mg/m2 in 6 cycles after SRT, or standard CRT 
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followed by adjuvant chemotherapy, with the hypothesis that the experiment group will increase 
the 3-year DFS from 50-60 %. The results will be available in 2020. A polish trial with a similar 
intention included patients with fixed cT3 or cT4 tumours and randomly assigned them to con-
ventional CRT or three cycles of FOLFOX after SRT. No difference in R0 resection, DM, post-
operative or late complications could be found but there was an improved OS in patients receiving 
consolidative chemotherapy.220 
Surgery for rectal cancer 
Except for patients with a complete tumour regression following (C)RT, surgery is required to cure 
patients with RC. Professor R. “Bill” Heald introduced the concept of TME in 1982 and showed 
excellent results regarding LR rates, even compared with modern materials with adequate 
preoperative staging, neo-adjuvant therapy and modern surgery. The technique consists of sharp 
dissection in embryological planes and excising rectum together with the whole mesorectum with 
blood vessels and lymph nodes as an intact specimen covered with an undamaged endopelvic 
fascia.38 After the adaption of the TME-technique the frequencies of LR roughly halved in studies 
exploring RT-courses.33,127 Today, LR frequencies are as low as 3 % in low-risk tumours in Sweden.2  
Anterior resection 
Anterior resection (AR) is one of the standard procedures in surgery for RC. In patients with a 
cancer in the mid or low rectum, AR is the preferred technique, given that the patient tolerates an 
anastomosis. Preoperative impaired sphincter function or faecal incontinence are often considered 
a contraindication for this approach. Surgery is performed with the TME-technique and to 
minimise the risk of LR it is important to do a full TME and not leaving any mesorectum behind. 
71 The bowel is usually transacted distally just above the pelvic floor. In high tumours, especially 
above the peritoneal reflection, a partial TME may be performed, with the ambition of better 
functional outcomes. However, there is clearly a risk of underestimating the need of radical surgery 
in the high tumours.221 The continuity of the bowel is restored performing a anastomosis, most 
often by a circular stapling device. To reduce the number of symptomatic AL, a defunctionting 
stoma reduces reduce the frequency of early diagnosed leaks.222  
Hartmann’s operation 
The procedure where a part of the left colon is excised and an end- colostomy is brought up, is 
known as the Hartmann’s procedure, first described in the early 1920s.223,224 The indication of today 
in cancer surgery is in patients not fit for an anastomosis.225 
Abdominoperineal excision 
The abdominoperineal excision, (APE) and its modifications are primarily used for low RC when 
a radical excision cannot be guaranteed without removal of also the sphincters. In short, APE 
includes removing of the whole rectum, by TME-technique, including the anal canal, and 
consequently constructing an end stoma. Or with the words of the founder “an abdominal anus is a 
necessity”. 226 Both perineal and combined abdomino-perineal approaches had been used since the 
1880s but with poor results. Miles described a case series of 12 patients in the Lancet 1908, with 
an impressive reduction in the frequency of LR. The 42 % mortality was found acceptable, 
considering the natural course of the disease. The paper had an huge impact on the surgical society 
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and APE was considered the standard procedure in RC surgery for a long time. Today, APE is 
usually divided in to four sub types. The intersphincteric, conventional, extralevator (ELAPE), and 
the ischioanal APE.227 The intersphincteric APE is mainly an alternative to Hartmann’s procedure. 
Instead of leaving a stapled rectal stump at the level of the pelvic floor the entire rectum with the 
anal canal is excised by an intersphincteric dissection. The potential advantage is that problems 
from the stump, such as abscesses are avoided. Differences in surgical morbidity is currently 
explored in a trial.228 
In a conventional APE the abdominal part extends all the way down to the pelvic floor. The 
perineal part includes excision of the sphincters and the anal canal where after the specimen is 
extracted. The risk of the approach is a retraction, or waist, just above the levator muscle, with risk 
of threatened margins in this area. In patients with really low or advanced tumours, involving the 
sphincters, the outcomes were known to be inferior compared to higher tumours. With the 
ambition of avoiding this, the ELAPE was introduced.229 The concept is that the abdominal part 
ends at the level of the coccyx and the perineal excision line, from below, follows the outer edge 
of the external sphincter and continues below and along the levator muscles until the insertion 
onto the pelvic sidewall, resulting in an almost cylindrical specimen, with theoretically a greater 
lateral resection margin. The pelvic floor defect often requires mesh- or flap reconstruction. A 
superior CRM and lesser perforations after ELAPE have been confirmed in studies.230,231 However, 
the operation has been questioned by others in respect of wound healing, perineal hernias and a 
not convincing oncological superiority.232,233 
The ischioanal APE is the most extensive excision, and is indicated in patients with large locally 
advanced cancers involving the perineal skin or ischioanal compartment. The incision line follows 
the fascia of the internal obturator muscle instead of the external sphincter, as in ELAPE. 
Minimal invasive techniques 
The use of minimal invasive surgical techniques has gained popularity during the last two decades. 
The surgical community in Sweden has been a late adopter, but now about 60 % of the patients 
are operated with minimal invasive techniques.2 The advantages with laparoscopy compared to 
open surgery includes reduced time to recovery, return to bowel function and length of stay. The 
oncological results have been considered similar.234-237 However, the operating time is longer and 
other trials have not concluded non-inferiority in terms of quality of the specimen.238,239 Robotic 
assistance is proposed to overcome some of the limitations of standard laparoscopic surgery, i.e 
better 3-D visualisation and articulation of instruments. Small studies, often case series, have 
supported the use and efficacy, but the multicentre randomised ROLARR trial concluded that 
robotic assisted surgery is of no advantage in RC surgery.240 The main outcome was conversion 
rates. No data on survival or long-term outcomes are available yet. The place for robotic RC 
surgery still remains uncertain.  
The transanal TME (taTME) combines transabdominal laparoscopic resection and a transanal 
TME-dissection using a gel-platform and endoscopic instruments. It can be carried out with two 
surgical teams simultaneously. There might be advantages in male patients with narrow pelvises 
or in the obese patients. However, the technique is relatively new and the oncological safety has 
to be confirmed in prospective studies.241 
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Local excision 
Since complications after RC surgery are common, techniques with the ambition of a local excision 
have developed. Main indication is early tumours, such as polyps or Tis, but it has also been 
introduced in cancers. As discussed previously the techniques may also have a place in tumours 
with good response after neo-adjuvant therapy.183-185 The simplest approach is transanal excision, 
often using some kind of retractor to facilitate visual exposure. The goal is a full thickness excision 
with 1 cm margin. With the TEM a resectoscope is used and the visualisation is improved, however 
the cost is high and there is a steep learning curve.242 Compared to TME-surgery in T1 tumours, 
TEM results in significantly less morbidity and shorter length of stay, however with a higher risk 
for LR.243 Further, if TME-surgery has to be performed as a completion to the TEM, the 
embryological planes might be disrupted and the surgery need to be more extensive.244 The 
TAMIS, transanal minimal invasive surgery, uses the same concept as the TEM, but with more 
standard laparoscopic instruments. Other endoscopic techniques include endoscopy submucosal 
dissection (EMD) or the endoscopic mucosal resection (EMR).  
The short term adverse events after RC surgery involves the common complications seen after 
any type of major surgery such as wound infections, general infections, bleeding and 
thromboembolic events. There have been a number of ways of reporting and register post-
operative complications, the lack of conformity makes comparison between studies 
challenging. A system of grading complications was introduced by Clavien et. al and has been 
accepted by the surgical community and was introduced in the SCRCR in 2011.245
One of the most detrimental complications is the AL after AR. The effect is a pelvic infection, 
with risk of general sepsis, often requiring a second operation, and in worse case converting 
the AR to a Hartmann’s procedure. About 2/3 of patients with AL will end up with a 
permanent stoma.246 The frequency of AL after AR is about 10 %, in defunctioned 
patients.222,247,248 Male sex, malnutrition, and high body weight increase the risk.249 In a pooled 
analysis, the use of neo-adjuvant therapy does not seem to be a strong risk factor for AL.250 
Perineal wound complications following APE is a major problem seen in at least 20 % of the 
patients, in ELAPE the complications are even more common.230 The use of (C)RT 
substantially increases the risk of perineal wound infections.202,251
Trying to minimize the post-operative complications has been the focus from several point of 
views. Minimal invasive techniques generally shortens length of stay and reduces peroperative 
blood loss and postoperative pain.252 The risk reduction for major complication, such as AL or 
need of reintervention does not seem to differ. In the COLOR II trial 40 % of patients 
operated with open technique had any complication compared to 37 % operated by 
laparoscopy, p=0.424.235 Smoking cessation for at least 4 weeks prior to surgery reduces the 
risk of complications with almost 50%, in a mixed surgery cohort.253,254 Introduction of 
enhanced recovery programs (ERAS) have gained popularity.255 Among other gains such as a 
shorter length of stay, there is up to a 50% reduction of postoperative complications.256 In a 
meta-analysis it was concluded that the risk reduction is primarily seen in non-surgical 
complications, such as respiratory and cardiovascular events.257
Post-operative complications 
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Another way of optimising the patient before surgery is the concept of prehabilitation, which is a 
wide group of interventions with the aim of an overall improved physical state. It is proposed 
that these interventions improve the capacity to deal with the stress of major surgery with a 
subsequent improved post-operative period. Review articles have found conflicting results on 
these programs, mainly due to the heterogeneity of the studies and focus on single risk-factors in 
the included studies.258-260 At least, the idea of “prehab” does not seem to have any negative 
outcomes, and international randomised trials are ongoing.261
Although promising evolvements have been made, the level of postoperative complications in 
the SCRCR has remained rather stable for the last two decades. Around 35 % of the patients are 
registered with some form of complication. In the last two years there might be trend towards a 
decline in the frequency.2 
Adjuvant chemotherapy 
In colon cancer there is evidence that adjuvant chemotherapy reduces the risk for recurrences, and 
improves survival in stage III disease. Further, adjuvant therapy is often used for patients in stage 
II with risk multiple risk factors.262-264 In RC, the benefits have been harder to show. A Cochrane-
review concluded that OS was improved by adjuvant chemotherapy HR (95 % CI) 0.83 (0.76-
0.91).265 However, the included trials were published between 1981-2011, before the TME-era, and 
only two trials included patients with neo-adjuvant treatment. A more recent meta-analysis used 
pooled individual patient data from trials including patients who had neo-adjuvant treatment.266 
No benefits in OS or DFS were found, pooled estimate HR DFS 0.9 (0.77-1.07) p=0.230, OS 0.97 
(0.81–1.17) p=0.775. In a sub-group analysis DFS, but not OS was improved in high tumours HR 
DFS 0·59 (0.40–0.85) p=0.005, OS 0.70 (0.44–1.14) p=0.152. Another meta-analysis concluded a 
positive effect on DFS, HR 0.79 (0.61-1.00) p=0.0047, analysing patients randomised after surgery, 
i.e were “at risk” of receiving chemotherapy (n=753).267 However, no positive effect on OS was 
found. 
Although the level of evidence is moderate, at best, the use of adjuvant chemotherapy is rather 
common. The ESMO-guidelines consider it “reasonable” to consider adjuvant treatment in 
patients with RC but it should be assessed on individual basis. Both the American and Japanese 
guidelines recommends adjuvant chemotherapy in stage III RC.103,104 
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Aims of the thesis 
The overall aim of this thesis was to improve treatment and outcomes of patients with rectal 
cancer, by comparing preoperative courses of RT and timing of surgery. Focus has been on 
oncological outcomes, radiation toxicity, postoperative complications and tumour response. The 
specific aims of the four studies were: 
I. To analyse the early adverse events, oncological outcomes and survival in the 
Stockholm III trial.  
II. To analyse the postoperative complications in the Stockholm III trial, in relation to the
exact timing of surgery.
III. To assess tumour regression, histopathology outcomes and correlation to survival and
recurrence in the Stockholm III trial.
IV. To analyse the long-term oncological outcomes and survival in the Stockholm III trial
after a minimum follow up of 5 years.
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Patients and Methods 
The Stockholm III trial 
The patient cohorts in all the studies in this thesis derive from the Stockholm III trial. A summary 
of the studied cohorts and outcomes are presented in Table 1. On the 5th October 1998 the first 
patient was enrolled and last patient entry was 31st January 2013. The design was a randomised, 
non-blinded, multicentre, non-inferiority trial. Eligible patients had a biopsy proven 
adenocarcinoma of the rectum without signs of distant spread and were planned for an abdominal 
surgery. Exclusion criteria were severe cardiovascular comorbidity and/or previous RT to the 
pelvis. Patients were randomised between three different RT courses: 
1) SRT                   5 Gy x 5 and surgery within one week.
2) SRT-delay 5 Gy x 5 and surgery after 4-8 weeks. 
3) LRT-delay 2 Gy x 25 and surgery after 4-8 weeks. 
Including hospitals could choose to randomise patients between SRT or SRT-delay, or between 
all three arms. Some hospitals did not include patients in the three armed randomisation, and 
some hospitals did not include in all arms during periods of the year due to logistic reasons. 
Primary end-point was time to LR. Secondary outcomes were survival, distant metastases, 30-day 
mortality, postoperative complications, reoperations, sphincter saving surgery and late morbidity. 
Based on studies that included patients in the 1980s and 1990s the frequency of LR was estimated 
to be about 15 % and five-year survival 60 %. Non-inferiority, regarding the primary outcome, 
was too be deemed if the upper limit of a double sided 90 % CI (corresponding to a significance 
level of <0.05) of a HR did not exceed 1.7. To achieve a power of 80 % the total sample size was 
set to 840 patients. Early after study start it became obvious that the introduction of modern 
surgical techniques (TME) and optimised RT would affect the frequency of LR in the future. An 
amendment 
Table 4. Study cohorts and outcomes in the thesis
Cohort Primary outcome Secondary 
outcomes 
Eligible 
patients 
Included in 
main analysis 
Study I All patients in the 
Stockholm III trial 
Time to local 
recurrence 
Radiation toxicity, 
metastases, survival, 
postoperative 
complications  
840 840
Study II Patients with 
surgery and RT in 
the Stockholm III 
trial 
Postoperative 
complications in 
relation to overall 
treatment time 
Early mortality 830 810 
Study III Patients with RT, 
surgery and available 
specimens in the 
Stockholm III trial 
Tumour 
regression in 
relation to 
treatment 
Survival and 
recurrence in 
relation to tumour 
regression 
730 697
Study IV All patients in the 
Stockholm III trial 
Time to local 
recurrence 
Incidence of 
metastases, survival. 
840 840 
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to the initial study protocol was made. It 
was concluded that the HR to determine 
non-inferiority would be considerably 
higher if the sample size was not revised. 
This was however accepted and the trial 
continued with unchanged number of 
patients. Further, tumour regression and 
quality of life were added as secondary 
outcomes. Patients were initially recruited 
from the Stockholm/Uppsala region. 
With time, other centres showed interest 
and joined the trial. A total of 18 centres 
included patients, (Figure 8). TME-surgery 
was performed as AR, APE or 
Hartmann’s procedure. Antibiotic and 
thrombosis prophylaxis were administered 
according to local routines. 
RT planning and delivery have followed 
the local- and national guidelines and have 
somewhat varied over the years. In brief, 
RT was delivered with a four field box 
technique, with high-energy photons (8-20 
Gy). Individual 3-D dose planning and 
multileaf collimators were used at some 
hospitals towards the end of the trial. 
Target limits were drawn 3-4 cm above the 
anal verge or 5 cm below the tumour. The 
anal canal was included in the target 
volume only if an APE was planned. The 
upper limit was usually mid L5. The lateral 
limits of the anteroposterior beams extended 1–1·5 cm outside the pelvic rim.The anterior limit 
was sufficiently ventralto cover the obturator nodes, the entire mesorectum with tumour 
extension and the nodes along the internal iliac vessels. 
Registry data 
The SCRCR was used as the electronic clinical registration form (eCRF) and data from the registry 
have been used in all studies. Data registration was done by the local physicians. As standard, data 
are reported to SCRCR; at surgery, at follow up after 1, 3 and 5 years, or when an event occurs. 
Due to low completeness and low comparability in certain variables in the registry, data were 
validated in the patients’ medical charts.28 All hospital records from date of surgery and the 
following 30-days, including the first out-patient visit were analysed with the respect of type of 
surgery and post-operative complications. Further, fractionation of RT and radiation toxicity were 
also validated. The local physicians were asked to make an extra report to the registry on patients 
who were in between the ordinary reporting times at time for data extraction from the SCRCR. 
Figure 7. Graphical presentation of number of included 
patients/centre. Region of Stockholm is enlarged. Quantity 
is indicated both in colour intensity and size of bubble, 
number indicates upper limit per bubble. For exact number 
of patients please see appendix in paper I.
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With help of the regional cancer centre in Stockholm, data were collected from the regional cancer 
centre in the Northern region of Sweden, which administrates the registry. Two data files were 
received at two occasions. One in 2015 and one in the autumn of 2018. In 2017 a new reporting 
system was introduced in the SCRCR. This resulted in difficulties in 2018 when data were to be 
collected for the 5-year follow up. It took several revisions and a lot of data processing and 
merging before the data finally were ready for analyses.  
Analyses of randomised clinical trials 
Randomised clinical trials (RCT)s have been considered high level of evidence for many decades. 
The hierarchy of scientific evidence is often described as a pyramid, with meta-analyses placed at 
the top, followed by RCTs. The exact hierarchy cannot be determined by study design only, one 
must also consider the quality of the studies.268,269 When incorporating clinical studies in practice 
guidelines there is a need of grading the quality of the underlying studies. The GRADE working 
group has developed recommendations on these issues, taking quality, benefits and harms and 
costs in to account.270 When starting the Stockholm III trial, the knowledge of the SRT-delay was 
limited  and any retrospective study would have been impossible. Hence, a RCT-design was cho-
sen. 
The major advantage by randomising patients is that potential confounders are evenly 
distributed in the groups. When this is achieved, analyses can be carried out without adjustment 
for confounding factors. However, there might be problems when analysing and interpreting the 
data, especially when dealing with loss-to follow up or protocol violations. In the Stockholm III 
trial patients could violate the protocol in several ways. Patients could receive no RT at all. RT 
could be fractionated in another way than allocation prescribed. The timing of surgery could be 
wrong, both too short or too long according to randomisation, or it could fit the time interval of 
another arm. Further, some patients had no surgery, and a few patients had only local excisions. 
One way of tackling these issues are to analyse RCTs according to intention to treat (ITT). The 
basic idea is that all patients are analysed in the groups they initially were allocated to, independent 
of non-compliance or violations. Thereby avoiding too optimistic estimates when removing the 
“violators” and accepting that noncompliance and protocol deviations are likely to occur in actual 
clinical practice too. 271,272 However, when analysing trials according to ITT and thereby 
categorizing patients as they got a treatment they never received, the treatment differences might 
be diluted. Another way of grouping patients is “per-protocol” which often is defined as only 
patients that received one of the allocated treatment are analysed. The third option is “as treated” 
analyses, where patients are analysed in the regimen they de-facto received, this is sometimes 
referred to as a “modified ITT”.273 Both the latter ways potentially introduce biases in the 
analyses and should be undertaken with caution. In the present thesis, study I and IV were 
analysed according to ITT. In paper II, the aim was to analyse subgroups and ITT-analyses were 
not applicable. The patient cohort of study III was a subgroup of the Stockholm III trial, and the 
main outcome was a secondary outcome in the trial, therefore patients were analysed “as-
treated”.
28│PATIENTS AND METHODS 
Survival estimates 
Survival estimates were calculated in study I, III and IV. OS is often considered as the most 
important outcome in many research areas, including adjuvant cancer trials. However, several 
different outcomes are used as surrogate endpoints, with somewhat varying definitions in the 
literature. Punt et al. conducted a review article with the ambition of a consensus definition of the 
most commonly used end points in colorectal adjuvant trials (Table 5).274 It was concluded that 
DFS is the most appropriate primary outcome since it includes relevant events, is robust against 
bias and is observed earlier than OS. Time to recurrence (TTR) was seen as the most sensitive 
endpoint with respect of specific benefits from treatments, due to the exclusion of non-cancer 
related death.  
The probably most commonly used method for survival estimates in medical statistics is the 
Kaplan-Meier (KM) method.275 The graphical presentation was originally intended for OS-
analyses, a guaranteed event eventually, taking differences in follow up time in to account. Patients 
are censored when lost to follow up or at end of study. Hence, they contribute with information 
that no event occurred up to that time point. Differences in KM-curves are often tested by the 
log-rank test, a non-parametric test that compares the expected number of deaths (events) in one 
group with the total number of events when combining the groups, p-value is calculated from an 
approximate χ2-test.276  
Cox regression 
One way of comparing survival estimates is the Cox regression, a proportional-hazards model. 
Basically it describes mortality rates at any given time point. In the basic model, the ratio between 
two hazards is assumed to be constant regardless of time. The result is presented as a hazard 
ratio. To assess the proportionality of the hazard functions a visual inspection using Schoenfelds 
residuals are commonly used.277 The mortality rates might not be constant across categories, such as 
including hospital in a multicentre trial. In those situations, a stratified Cox-regression might be 
used, allowing for the baseline risk to vary across categories. 
Table 5. Survival outcomes Endpoint   
Event  DFS  RFS  TTR  TTF  CSS  OS  
Locoregional recurrence E E E E I I 
Distant metastases E E E E I I 
Second primary, same 
cancer  
E I I E I I 
Second primary, other 
cancer  
E I I E I I 
Death from same cancer  E E E E E E 
Death from other cancer  E E C E C E 
Non–cancer-related death E E C C C E 
Treatment-related death  E E C E C E 
Loss to follow-up C C C C C C 
DFS = disease-free survival; RFS = relapse-free survival; TTR = time to recurrence; 
TTF = time to treatment failure; CSS = cancer specific survival; OS = overall survival; 
E = event; C = censor; I = ignore. Reprint with permission from Punt et al.274 
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Cox regression, stratified on including centres has been used in study I and IV. In study III no 
stratification was done, due to the as-treated analyses. 
Competing risks 
KM-estimates have been criticised for over-estimating the risk of an event in the case of competing 
risks.278 For example, say RFS is the outcome of interest. Then LR, DM and death would be the 
events used for calculation of the RFS-estimate. The KM-method assumes that patients 
experiencing a competing risk, have the same probability of the event as patients that are censored, 
thus over-estimating the cumulative incidences. The ambition when taking competing risks in to 
account is to get results that better mirrors the reality. Several ways of dealing with this issue have 
been proposed. The basic idea is to use “cumulative incidence functions” that gives proportions 
of patients who have experienced the event, accounting for the fact that other events could have 
happened. The result will differ from a cause specific hazard, estimated by for instance the KM-
method. Competing risks were calculated in paper I. 
Other statistical methods 
Pearson’s χ2-test is used for statistical hypothesis testing between groups with categorical data. The 
test is based on the difference between expected and observed frequencies in the groups. If the 
sample size is very small, about less than five, Fisher’s exact test should be used instead. These two 
tests have been used in all four studies.  
For testing continuous variables, the Mann-Whitney U test (Wilcoxon rank-sum test) or the 
Kruskal-Wallis test were used, the latter when comparing more than two samples with non-
normally distributed (skewed) continuous data. The test is based on difference in variance between 
the groups. Hence, it assumes equal distribution in the compared groups. These tests have been 
used in paper I-IV. 
Binary data are often compared using logistic regression. An advantage with regression models is 
the possibility of adjustments with several covariates in one model, the result is most often 
presented as OR. Logistic regression was used in Study I, II and IV. Estimates are presented as 
crude and adjusted OR. 
If not otherwise specified, point estimates are accompanied with 95 % confidence intervals (CI) 
and the statistical significance level is p < 0.05. In all studies, Stata v. 13 -14.2 (Stata Corp LP, 
College Station, Texas, USA) have been used for statistical calculations. Some graphs in study III-
IV and the cover image were constructed using R v. 3.5.1 (R foundation for Statistical computing). 
Specific considerations 
Study I 
All patients in the Stockholm III trial were included (n=840). Data from the SCRCR were collected 
with the last day of follow up of 30th March 2015, when all patients had been followed for at least 
2 years since surgery. Previous interim analyses revealed a difference in tumour height and a 
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subsequent higher proportion of AR in the LRT-delay group. 152 This, in combination with the fact 
that some centres did not randomise patients in the three-armed randomisation at all led to the 
decision to analyse patients in the three armed randomisation separately, to avoid a bias 
introduction. Patients randomised to SRT and SRT-delay, irrespective of randomisation were 
pooled and analysed in a short course RT comparison.  
Primary outcome was time to LR and secondary outcomes were DM, intercurrent death, RFS and 
OS. These outcomes were calculated from day of randomisation to time of event. Other endpoints 
were radiation toxicity, defined as RT related symptoms requiring hospitalisation between start of 
RT and surgery. Post-operative complications within 30-days, or same hospitalisation period as the 
primary surgery, were also analysed. Complications were defined as any cardiovascular, surgical, 
infectious, neurological complication. Surgical complications were defined as any wound 
dehiscence, postoperative bleeding, surgical site infection, stoma-related complication, deep 
infection, anastomotic leak, complication, or other surgical related adverse event.  
Study II 
In this subgroup analysis patients were analysed as-treated. Patients were categorized in to groups 
based on their OTT, calculated from start of RT to day of surgery. Hence, patients without surgery 
or RT were excluded. Patients who received 5 Gy x 5 (SRT) were categorized into four groups. A 
– 7 days, B 8-13 days, C 5-7 weeks, D 8-13 weeks. Patients who received LRT-delay was
categorized in two groups E 9-11 weeks, F 11-14 weeks. Groups A-D were compared separate 
from group E and F. Outcomes were post-operative complications. The same definition as in 
study I was used. In addition, any type of infectious complication was also analysed. Differences 
between the groups were analysed using descriptive statistical methods. OR for complications were 
calculated using logistic regression and presented as crude and adjusted point estimates. Variables in 
the adjusted model were; ASA-score (American society of anaesthesiologists), sex, old age > 75 
years dichotomized, and type of surgical operation. These variables were selected based on data 
showing that male sex, high ASA-score and APE are associated with more post-operative 
complications.279-282 This clinical knowledge could also affect the decision on timing of surgery. 
Old age was considered a confounder since elderly patients might be selected to different waiting 
intervals, and have inferior outcomes when analysed stratified by OTT.144 In the SRT-comparison, 
group B was defined as the reference group. 
Study III 
In this study, the main outcome was tumour regression in the treatment arms. All available 
histological slides from patients in the Stockholm III trial were retrieved from the local pathology 
departments that initially prepared them. Blinded to allocation, one experienced GI-pathologist 
have reassessed them. The regression system according to Dworak was used (0-4).83 Other assessed 
histopathological characteristics were T-stage, N-stage, CRM, PN, EMVI, and tumour 
differentiation. pCR was defined as ypT0N0, given that both variables were assessable. Secondary 
outcomes were OS and TTR in relation to grade of tumour regression. Main analyses were 
conducted in the as-treated groups SRT, SRT-delay and LRT-delay. In the survival- and recurrence 
analyses all patients with assessable specimens were included. Based on previous studies, the most 
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interesting comparison was considered to be between Dworak regression grade 3 and 4. Thus, 
Dworak regression groups were reclassified in to three groups, 0-2, 3 and 4. 
Study IV 
In this study, the main outcome of interest was time to LR, after a minimum follow up of 5 years 
since surgery. Secondary outcomes were DM, RFS and OS. All patients (n=840) in the Stockholm 
III trial were included. Data were collected from the SCRCR with last day of follow up of 31st 
March 2018. The study was analysed according to ITT. An additional as-treated analysis was per-
formed. Patients were categorised in to groups based on the actual treatment they received and by 
OTT. Since the weekday of RT-start, and the exact OTT may vary due to holidays and other 
reasons, the OTT defining the “as –treated groups” were: SRT 7-13 days, SRT-delay 33-67 and 
LRT-delay 57-94 days, thus corresponding to having surgery performed within one week or 4-8 
weeks after the end of RT. 
Cover image 
In an attempt of summarizing this thesis in one image, inspiration was found in a beautiful 
ambition of describing uncertainty in statistical models by a visually-weighted regression, or 
“watercolour regression”.283 The concept was further elaborated and the R-script was shared online 
in 2012.284 The plots in the cover image were constructed based on these ideas and codes. In short, 
an unadjusted generalized linear model using the binomial distribution was fitted. Non-parametric 
locally weighted scatterplot smoothers (LOWESS, span=0.95) were calculated using 500 bootstrap 
samples from the trial data, generating the spaghetti plots. Every smoother has a high transparency 
(low alpha value). Hence, areas with a high density of overlapping smoothers will turn more intense 
and opaque, indicating a higher degree of certainty. The median smoother is indicated by a white 
line. The contrast to the background smoothers corresponds to the certainty of the median 
estimate. Every bootstrap sample is surrounded by a shade, causing the water colour effect. The 
shading intensity is based on density estimates of vertical cuts through the smoothers. In this 
graphical presentation, all bootstrap estimates are plotted. Consequently, the spaghettis with 
shading basically corresponds to a full CI. For the graphical presentation, only patients receiving 
5x5 Gy and OTT < 11 weeks are included. Complications are the probability of any post-operative 
complication. Recurrence is the probability of any local- or distant recurrence at 5 years. Regression 
is the probability of a pCR. 
Ethics 
The Stockholm III trial was approved by the ethics committee at Karolinska Institute, Stockholm, 
Sweden. 
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Results 
A summary of the main results in this thesis are presented in Figure 8 (also on the cover). It is a 
visualisation of proportions of complications, recurrences (LR or DM) and tumour regression in 
the Stockholm III trial. The outcomes are presented by OTT, calculated from start of RT to 
surgery. The hypothetical first day of RT is 5th October 1998, as an homage to the first included 
patient in the trial. This is a graphical presentation of a subset of patients in the Stockholm III trial, 
initially planned for decorative use. For this reason, the LOESS-curves might be considered a bit 
under fitted, and the uncertainty overestimated due to the shading. However, the plots clearly 
indicate that conclusions from the Stockholm III data are most valid in patients with surgery within 
one week, or after 4-8 weeks after RT. In patients in between or beyond these intervals, the grade 
of uncertainty is higher. 
Figure 8. Proportions of three outcomes in the Stockholm III trial, by overall treatment time (OTT) calculated from 
radiotherapy start on 5th October 1998. Patients receiving 5x5 Gy and OTT < 11 weeks are included. Complications 
are any post-operative complication. Recurrence is any local- or distant recurrence. Regression is complete pathologic 
response. 
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Study I 
In total, 840 patients were randomised in the Stockholm III trial. 385 in the three armed design 
and 455 in the two-armed. Basic patient characteristics were similar in all the randomised groups 
but there was a higher median tumour height in the LRT-delay group and consequently a lower 
proportion of APEs in this group, 19% vs 33% and 41%. (Table 6). About 6-7 % of the patients 
required in-hospital care due to side effects of RT between RT-start and surgery in SRT-delay 
and LRT-delay. One patient allocated to SRT was registered with RT-toxicity (protocol violator 
with OTT=196 days). There were statistically fewer overall- and surgical complications in SRT-
delay vs. SRT in the short RT comparison, OR any complication: 0.61 (0.45–0.83) p=0.001. In 
the three-armed comparison the frequency of complications was lower, but not statistically 
significant, in SRT-delay and LRT-delay compared to SRT. In total, LR was seen in 25 of 840 
patients. No statistical significant differences were found between the groups regarding LR, DM, 
OS, and RFS, neither in the short RT comparison, nor in the three-armed comparison, (Figure 9 
and Figure 10). A summary of the oncological outcomes in the short RT comparison is 
presented in Figure 11.  
Table 6 Baseline characteristics and type of surgery by allocated treatment 
Three armed randomisation Two armed randomisation 
SRT (n=129) SRT-delay 
(n=128) 
LRT-delay 
(n=128) 
SRT
(n=227) 
SRT-delay 
(n=228) 
Age (years) 67 (62-74) 67 (62-75) 66 (61-73) 67 (61-74) 67 (61-74) 
Gender 
Male 81 (63%) 79 (62%) 73 (57%) 137 (60%) 134 (59%) 
Female 48 (37%) 49 (38%) 55 (43%) 91 (40%) 93 (41%) 
Height from 
anal verge 
0-5 cm 50 (39%) 57 (45%) 31 (25%) 78 (34%) 68 (30%) 
6-10 cm 49 (38%) 49 (39%) 60 (48%) 91 (40%) 95 (42%) 
11-15 cm 30 (23%) 21 (17%) 35 (28%) 58 (26%) 63 (28%) 
Type of surgery 
AR 79 (61%) 68 (53%) 93 (72 %) 139 (61%) 136 (60%) 
APE 47 (36%) 53 (41%) 24 (19%) 75 (33%) 79 (35%) 
Hartmann's 3 (2%) 6 (5%) 8 (6%) 14 (6%) 12 (5%) 
Local 
excision 
0 (0%) 1 (1%) 1 (1%) 0 (0%) 0 (0%) 
No resection 0 (0%) 0 (0%) 2 (2%) 0 (0%) 0 0(%) 
Data are median (IQR) or n(%). SRT=short course radiotherapy 5 Gy x 5 surgery within one week. SRT-
delay = short course radio therapy, 5 Gy x 5, with a delay of 4-8 weeks to surgery. LRT-delay = Long 
course radio therapy, 2 Gy x 25, with a delay of 4-8 weeks to surgery. AR=anterior resection. 
APE=abdominal perineal excision. Reprint from Study I. 
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Figure 9. Outcomes in the short RT comparison. A) Local recurrences. B) Distant metastases. C) Recurrence Free Survival. D) 
Overall Survival. Reprint from Study I. 
Figure 10. Outcomes in the three armed randomisation. A) Local recurrences. B) Distant metastases. C) Recurrence Free 
Survival. D) Overall Survival. Reprint from Study I. 
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Figure 11. Summary of oncological outcomes in study I. * 90 % CI. Grey line indicates the inital non-inferiority level of 1.7.
Modified from study I. 
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Study II 
In the Stockholm III cohort seven patients never received any RT. Two patients never had surgery 
and one had a local excision. These patients were excluded from this study. Further, 20 patients 
had OTTs in between or beyond the OTT in the pre-specified groups. Hence, 810 patients were 
analysed, Group A n=100, Group B n=247, Group C n=192, Group D n=160, Group E n=52, 
Group F n=59. The distribution of patients by OTT is presented in Figure 12. Patients excluded 
from the groups had no statistical significant differences in basal patient characteristics compared 
with the included patients. Hence, no obvious reason to violate the study protocol with respect of 
timing of surgery was found. Patients that received 5 Gy x 5 (Group A-D) and patients that re-
ceived 2 Gy x 25 (Group E-F) were analysed separately. Baseline patient characteristics between 
group A-D and E-F were not significantly different. The most common post-operative 
complication was surgical site infection seen in about 21 % of the patients in total. In the short 
course RT comparison, the highest frequency of postoperative complications was found in group 
B (OTT of 8-13 days). The lowest complication risk was found in patients with the longest OTT, 
(Figure 13). We found no statistically significant differences in the proportion of complications  
when comparing Group E and Group F. There were very low numbers of 30- and 90-day 
mortality in the trial, and the frequency did not significantly differ between the groups. As a 
sensitivity analysis the 20 patients initially excluded from the study were put into the groups, 
without changing the results. When analysing the infectious complications without surgical site 
infections the results also remained stable. 
In this study OTT was used to categorize patients. The exact date at end of RT was not known. 
Hence, the waiting time between end of RT and day of surgery could not be calculated. However, 
the weekday of RT-start was known and it is possible to estimate the end of RT, assuming that no 
Figure 12. Number of patients by group and OTT. Grey is day of RT, blue is weekend, plum is delay, cyclamen is day of surgery. 
Modified from Study II. 
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surgery is performed or RT is given on Saturdays or Sundays. It was decided not to present this 
“estimated end of RT” in the original paper due to the uncertainties, especially in the groups with 
a delay to surgery (unknown holidays or logistic reasons, etc.). This supplementary analysis on 
patients receiving 5 Gy x 5 is presented here. Four groups were constructed, based on time from 
estimated end of RT to surgery; 0-3 days n=126, 4-7 days n=221, 28-41 days n=182, 42-85 days 
n=170. The interpretation of the results does not differ from the main analyses in any major way. 
The lowest frequency of complications was seen when surgery was delayed for more than 41 
days, (Figure 14). In the unadjusted analyses there was a statistical significant reduction of 
complications in the group with surgery after 0-3 days compared to 4-7 days, but the results did 
not remain stable after adjusting for covariates. In the adjusted model the reduction of infectious 
complications did not reach statistical significance in the group with surgery 28-41 days after 
SRT. 
Figure 14. OR of different types of complications, by estimated end of RT. 
Figure 13. OR for different types of complications, by OTT Group B is reference. Reprint from Study II. 
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Study III 
In total, 730 (86.9 %) of 840 specimens were available for reassessment. It was not possible to 
assess 45 specimens due technical reasons or missing slides. Due to unclear reasons at the local 
pathology departments, 65 specimens were not possible to retrieve. In the as-treated groups 318, 
285 and 94 patients were included in the SRT, SRT-delay and LRT-delay, respectively. Flowchart 
of the study and reasons for exclusions and cross-over are presented in figure 15. The ypTstage 
was significantly lower in the SRT-delay group compared to both SRT and LRT-delay (Table 7). 
TRG 0-2 was seen in 312 of 318 (98,1%) after SRT, indicating a low downstaging effect after 
immediate surgery. The lowest frequency of both EMVI+ and PN+ was seen after SRT-delay. A 
rather high frequency of missing CRM status was noted, 179 (25.7 %) of 697 patients. A positive 
CRM, defined as distance of <1 mm was seen in 31 (6.0 %) of 518 of the patients, without 
significant difference between the groups. pCR was virtually not seen before in OTT< 3 weeks. 
Patients with pCR had significantly improved TTR and OS compared to no-pCR. The difference 
remained significant also after adjusting for old age, sex and type of surgery. HR OS 0.51 (0.26;0.99) 
p=0.046, HR TTR 0.27 (0.09;0.86) p=0.027. Patients with specimens assessed as TRG 4 had better 
OS and TTR compared to patients with TRG 0-2, (Figure 16). When comparing OS and TTR in 
TRG 0-2 with TRG 3 or TRG 3 with TRG 4, no statistical differences were found. 
Figure 15. Flowchart of included patients in the as treated comparison. Crossover was possible when both fractionation and 
waiting interval matched another group. Reprint from study III. 
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Table 7. Pathology outcomes 
SRT SRT-delay LRT-delay p-value
N 318 285 94
ypStage ypStage 0‡ 4 (1.3%) 35 (12.3%) 3 (3.2%) <0.0001
ypStage I 86 (27.0%) 100 (35.1%) 27 (28.7%) 
ypStage II 107 (33.6%) 72 (25.3%) 36 (38.3%) 
ypStage III 109 (34.3%) 68 (23.9%) 24 (25.5%) 
ypStage IV 4 (1.3%) 4 (1.4%) 2 (2.1%) 
ypStage x† 8 (2.5%) 6 (2.1%) 2 (2.1%) 
ypT-stage ypT0 4 (1.3%) 30 (10.5%) 3 (3.2%) <0.0001
ypTis 2 (0.6%) 6 (2.1%) 2 (2.1%) 
ypT1 13 (4.1%) 34 (11.9%) 6 (6.4%) 
ypT2 100 (31.4%) 78 (27.4%) 27 (28.7%) 
ypT3 188 (59.1%) 124 (43.5 %) 54 (57.4%) 
ypT3 a/b 135 (42.5%) 90 (31.6%) 37 (39.4%) 
ypT3 c/d 50 (15.7%) 33 (11.6%) 12 (12.8%) 
ypT3 x 3 (0.9%) 1 (0.4%) 5 (5.3%) 
ypT4 11 (3.5%) 13 (4.6 %) 2 (2.1 %) 
ypT4a 3 (0.9%) 5 (1.8%) 1 (1.1%) 
ypT4b 6 (1.9%) 4 (1.4%) 1 (1.1%) 
ypTx † 2 (0.6%) 4 (1.4%) 0 (0.0%) 
ypN-stage ypN0 199 (62.6%) 211 (74.0%) 66 (70.2%) 0.046
ypN1 76 (23.9%) 48 (16.8%) 15 (16.0%) 
ypN2 37 (11.6%) 23 (8.1%) 11 (11.7%) 
ypNx † 6 (1.9%) 3 (1.1%) 2 (2.1%) 
EMVI+ Yes 124 (39.0%) 75 (26.3%) 35 (37.2%) 0.005
No 192 (60.4%) 204 (71.6%) 59 (62.8%) 
N/A 2 (0.6%) 6 (2.1%) 0 (0.0%) 
PN+ Yes 67 (21.1%) 25 (8.8%) 13 (13.8%) <0.0001
No 249 (78.3%) 254 (89.1%) 81 (86.2%) 
N/A † 2 (0.6%) 6 (2.1%) 0 (0.0%) 
Differentiation* Adenoma 1 (0.3%) 4 (1.6%) 0 (0.0%) 0.028
High 15 (4.8%) 24 (9.4%) 6 (6.6%) 
Moderate 251 (79.7%) 201 (78.8%) 79 (86.8%) 
Low 22 (7.0%) 10 (3.9%) 0 (0.0%) 
Mucinous 25 (7.9%) 16 (6.3%) 5 (5.5%) 
Signet ring 1 (0.3%) 0 (0.0%) 1 (1.1%) 
N/A † 1 (0.3%) 4 (1.6%) 0 (0.0%) 
CRM >1 mm 228 (92.3%) 193 (96.0%) 66 (94.3%) 0.26 
< 1 mm 19 (7.7%) 8 (4.0%) 4 (5.7%) 
N/A † 71 84 24 
Dworak TRG 0 29 (9.1%) 20 (7.0%) 4 (4.3%) <0.0001
TRG 1 233 (73.3%) 124 (43.5%) 42 (44.7%) 
TRG 2 50 (15.7%) 92 (32.3%) 37 (39.4%) 
TRG 3 2 (0.6%) 16 (5.6%) 7 (7.4%) 
TRG 4 4 (1.3%) 29 (10.2%) 3 (3.2%) 
N/A† 0 (0.0%) 4 (1.4%) 1 (1.1%) 
pCR 1 (0.3%) 29 (10.4%) 2 (2.2%) <0.0001
Numbers are n (%) if not otherwise specified. N/A not assessable. *ypT0 not included. †Not included in 
statistical calculation. ‡ Includes ypT0 and ypTis, Reprint from Study II. 
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Figure 16. Kaplan-Meier estimates by pCR, pathologically graded complete response, all patients with assessable ypT and ypN 
stages.  A Overall survival. B Time to recurrence. Reprint from Study III. 
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Study IV 
All 840 patients initially randomised in the Stockholm III trial were included in this study. Analyses 
were performed according to ITT. The three-armed randomisation was analysed separately and 
the patients randomised to 5 Gy x 5 +/- delay to surgery were analysed in a pooled short course 
RT comparison. Patient distribution by OTT is presented in figure 17. The median follow-up 
(IQR) in the SCRCR was 5.7 (5.3-7.6) years. Two patients were lost to follow 
up in the SCRCR after 2.5 years (SRT-delay) and 1.8 years (LRT-delay) respectively, for unclear 
reasons. The median follow-up time regarding OS was (IQR) 9.8 (7.7-12.6) years. 
Number of failure events in the three-armed comparison and pooled short RT comparison are 
presented in Table 8 and Table 9 respectively. Median OS (95 % CI) in the three armed randomi-
sation was 8,14 (6.94-11.24), 10,34 (8.16-12.76) and 10,53 (6.95-11.34) years in SRT, SRT-delay 
and LRT-delay respectively, (Figure 18). In the short RT comparison, the median OS (95 % CI) 
was 8.14 (7.23-9.98) and 10.18 (8.45-11.68) years in SRT and SRT-delay respectively, (Figure 19). 
No statistical significant differences were seen regarding the oncological outcomes between the 
groups. 
Figure 17. Number of patients by overall treatment time, grouped by allocated treatment. Patients without surgery, RT or 
OTT >13 weeks are excluded from figure (n=13). Bar colour indicates allocated treatment by randomisation. RT-violation 
– patients allocated to LRT-delay that received 5x5 Gy. Dashed lines corresponds to predefined time intervals within the
treatment courses. Intention to treat groups includes all patients independent of protocol violation. As treated groups includes 
all patients within dashed lines +/- a few days. 
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Table 8. Oncological outcomes and survival in the three armed randomisation. 
SRT SRT-delay LRT-delay
n 129 128 128
Any death 65 (50.4) 58 (45.3) 56 (43.8)
Intercurrent death 37 (28.7) 24 (18.8) 23 (18.0)
MET 31 (24.0) 38 (29.7) 38 (29.7) 
LR 3 (2.33) 4 (3.13) 7 (5.47)
SRT (ref) SRT-delay p LRT-delay p 
OS 1.0 0.75 (0.51-1.09) 0.137 0.88 (0.61-1.29) 0.512 
RFS 1.0 0.90 (0.61-1.21) 0.589 0.99 (0.63-1.30) 0.956 
Distant metastases 1.0 1.47 (0.90-2.42) 0.123 1.23 (0.76-1.99) 0.39 
Local recurrence* 1.0 1.18 (0.33-4.15) 0.830 2.23 (0.70-7.14) 0.236 
Data are n(%) or HR(95 % ) if not otherwise specified.*90 % CI 
Table 9. Oncological outcomes and survival in the short RT 
course comparison 
SRT SRT-delay 
n 357 355
Any death 200 (56.0) 211 (59.44)
Intercurrent death 84 (23.5) 68 (19.2) 
DM 88 (24.7) 82 (23.1)
LR 11 (3.1) 13 (3.7) 
SRT (ref) SRT-delay p
OS HR  1.0 0.84 (0.66-1.06) 0.146 
RFS HR 1.0 0.85 (0.68-1.06) 0.144
Distant metastases 1.0 0.94 (0.69-1.27) 0.692 
Local recurrence* 1.0 1.31(0.66-2.61) 0.518
Data are n(%) or HR(95 % ) if not otherwise specified.*90 % CI 
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Figure 18. Oncological outcomes in the three armed comparison. A Overall survival B Recurrence Free Survival, C 
Distant metastases D Local recurrence. p is log-rank test.
Figure 19 Oncological outcomes in the short RT comparison. A Overall survival B Recurrence Free Survival, C 
Distant metastases D. Local recurrence. p is log-rank test.
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Discussion 
Long inclusion period 
The Stockholm III trial was planned and initiated in a time when LR rates were considerably higher 
compared with today. Previous trials had shown an improved local control with RT compared to 
surgery alone and preoperative RT had been proven to be superior to post-operative ditto.122,124-126 
Naturally, the most important aspect of any new trial on adjuvant treatment in RC was to be certain 
that the experimental treatment was as good as the standard treatment with respect of LR. The 
choice of a non-inferiority design and time to LR as primary end-point, was the most obvious and 
interesting thing to do. In Sweden, two RT-courses were used for RC, 5 Gy x 5 or 2 Gy x 25- 
Randomisation between them with one additional experimental arm with a delay to surgery after 
5x5 Gy was chosen. The trial had a long inclusion period of 14.7 years. During the trial a lot of 
evidence evolved regarding the importance of TME-surgery, good quality of the surgical specimen, 
histopathological risk factors, MRI-guided stratification of neo-adjuvant treatment and improved 
MRI-staging.55,70,71,101,127 Further, the feasibility and safety of the SRT-delay regimen was explored 
and described outside the trial.149-151 Later, the addition of chemotherapy to LRT-courses was 
proven to improve local control and improve survival in unresectable tumours.131-133 During the 
latter part of the trial SRT was suggested to have similar oncological outcomes compared to CRT 
in T3/T4 tumours, which also had been showed in a Polish trial.141,142 However, the comparison 
between SRT and SRT-delay in a prospective setting had not been explored. When the interim 
analyses had proven safety and a possibility of tumour regression even after SRT-delay, more cen-
tres joined the trial and the recruitment got easier.152,174 The long inclusion period evidently has 
implication when interpreting the results from the Stockholm III trial. However, patients have 
been included in the trial and randomised to all arms during the whole time period. Thus, the effect 
on outcomes would be small on relative estimates. In study II and IV outcomes were stratified on 
inclusion period, without changing the results in any major way.  
One weakness in the Stockholm III trial is the lack of data on preoperative staging. In the original 
protocol, the use of preoperative MRI was vaguely advocated and data were not prospectively 
registered. MRI-staging became standard around 2003 and was introduced as a variable in the 
SCRCR from 2007. Hence, it is not easy to describe the study population with respect of baseline 
tumour stage. However, T-stage could be estimated from the ypStage. It has previously been 
described that no downstaging is seen in patients with an OTT<10 days after SRT.172,173 In the 
Stockholm III trial ypTstage was >3 in about 2/3 of the patients with OTT<10 days, and this is 
probably the closest estimate of the true value that can be calculated. 
SCRCR 
The SCRCR was used as the eCRF. Although the registry has been validated and many variables 
are proven to be reliable there is still a risk of missing data.28 Post-operative complications, radiation 
toxicity, type of surgery and some more variables were manually controlled in the patients’ medical 
charts. The analyses of LR and DM are based on registry data, and there might be a risk of missing 
events in the registry.27 The regular definition on “follow-up” in the SCRCR is that the patient have 
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been examined with appropriate radiology and by the responsible physician. If this not have been 
possible, a telephone call and a thorough assessment of the medical chart should have been carried 
out. We have asked the including centres to make additional reports on patients in the trial, thereby 
forcing extra audits of the medical charts. When data were collected to the first study, we noted 
that several centres had very few events registered in the SCRCR on patients included during the 
last 2-3 years. We asked the including centres to double check around 110 patients without any 
registered events, no additional events were identified. The levels of LR and DM in the study are 
also in line with what is expected. In general, there are both advantages and disadvantages with 
using quality registries as the eCRF. The main upside is the limited extra work for including centres, 
which may lead to a higher degree of participation, especially at centres without research facilities. 
The down side might be lower completeness of data. Further, the collection of data from the 
SCRCR for study IV was complicated by a new reporting system. In the case of Stockholm III, 
this must be considered as a minor problem since we have full control of the included patients and 
most events were before 2017. However, this might be an issue that threatens the validity of future 
studies based on SCRCR. 
Complications and toxicity 
In study I we explored the frequency of adverse events after RT and surgery in all three arms. We 
found significantly lower frequency of post-operative complications if surgery was delayed after 
5 Gy x 5, but also increased RT-induced toxicity in these patients. Pre-operative RT-toxicity was 
seen in about 6-7 % of the patients in SRT-delay and LRT-delay. Naturally, some of the “post-
operative” complications seen after SRT with immediate surgery is an effect of RT-toxicity. We 
have not tried to classify the post-operative adverse events as an effect of RT or surgery. In 
absolute figures, the total amount of complications is lower after SRT-delay compared to SRT 
(even with RT-toxicity included). However, since no grading of the severity of post-operative 
complications has been done, comparison of the total load of adverse events must be done 
with caution. Grade 3-4 RT induced toxicity must not be compared with surgical site infections 
or easily treated urinary tract infections.  
The Australian trial comparing SRT and CRT found no difference between the treatment groups 
regarding post-operative complications (53.2 % in SRT vs. 50.4% in CRT)143. In our material the 
post-operative complication rate was 50 % in SRT, 38 % in SRT-delay and 39 % in LRT-delay. 
When comparing these trials one could get the impression that the rate of complications is similar 
in CRT and SRT with immediate surgery. However, other studies found that CRT did not increase 
the risk for post-operative morbidity compared to surgery alone in a propensity-matched 
population, 29.3 % vs 31.3%.285 One meta-analysis exploring effect of neo-adjuvant therapy on 
morbidity concluded that CRT does not increase the post-operative complications, but morbidity 
is high after SRT with immediate surgery.286 Thus, timing of surgery matters. 
In study II we aimed at describing the post-operative complication profile in-detail by OTT. Other 
studies have described that surgery should be performed early in the waiting interval, due to poor 
leukocyte response if OTT is prolonged more than 10 days.145,146 In a sub-group of the Dutch TME 
trial it was shown that elderly patients even had worse survival if surgery was performed in the end 
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of the first week, but this was not found in a verification set of patients, analysed in the same study. 
144
We found that the lowest rate of any-, surgical or infectious complications was seen if surgery was 
delayed for at least 6 weeks after end of RT. No obvious benefit was found if surgery was 
performed early (0-3 days from RT, or OTT 7 days) One limitation of this study was that the last 
day of RT was not known. Therefore, patients were grouped based on OTT instead of “time from 
last RT fraction”. As a sensitivity analysis data were analysed with the estimated last day of RT, 
without changing the results in a major way. Other limitations included that data on comorbidities 
were highly limited. We used the ASA-score in the multivariate analysis as a surrogate for 
concurrent disease. Further, data on ASA-score was only available after 2007. Thus, the adjusted 
models are based on data from fewer patients than the crude model. Other missing variables that 
would be of interest are BMI and smoking status. Both which are known to affect the post-
operative outcomes.  
Would this lack of data affect the interpretation of the main result? First, a confounder must be 
associated with both the outcome and the exposure. It is not sure that the “missing comorbidities” 
would affect both the OTT and the post-operative outcome. Second, there were no statistically 
differences in baseline characteristics between the OTT-groups, indicating that the missing data 
are equally distributed in the OTT-groups. One other issue that not have been formally tested, is 
if the risk reduction varies over different “risk-stratas”. High risk patients will naturally gain more 
in absolute numbers, but speaking in relative terms, the risk reduction is probably similar for both 
high- and low-risk patients. To conclude, there are less complications if surgery is delayed but 
some of the effect might be explained by residual confounding. 
Are post-operative complications an end-point of importance? Apart from prolonging length of 
stay, increasing hospital costs and causing patient discomfort, it has been proposed that patients 
with severe post-operative complications have inferior oncologic outcomes. Mainly explained by 
a prolonged interval to, or disqualification of adjuvant chemotherapy.279,287 However, many of the 
studies exploring outcomes after complications have included both colon and rectal cancers in the 
comparisons. In studies that specifically analysed patients with RC, the results are conflicting.288-290 
In the Stockholm III trial no difference of severe complications such as AL or rate of reoperations 
was found between the treatment groups. In conclusion, the reduction of complications in the 
arms with the delay to surgery is not likely to affect the long-term oncological outcomes. 
Tumour regression 
In the Study III it was concluded that SRT-delay induces more pCR and higher tumour regression 
grades compared to SRT and LRT-delay. OS and TTR are improved in patients with pCR and 
TRG 4. The higher rate of tumour regression in SRT-delay compared to SRT is expected since 
there is no time for the tumour to regress if surgery is performed within one week.172,173 The 
comparison between SRT-delay and LRT-delay has not, to our knowledge, been explored in 
prospective studies before. The superiority of 5 Gy x 5 might be somewhat surprising since the 
BED has been considered to be similar in SRT and LRT. However, even if the α/β ratios are not 
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fully understood in RC, the results in our study must be interpreted with care. There are more 
“high” tumours in LRT-delay and there might exist some residual confounding factors. The very 
small number of TRG 4/pCR in LRT-delay did not allow for any multivariate analyses. 
In our material, TRG 3 had more similar outcomes compared to TRG 0-2, even though the 
histopathological findings were more like TRG 4. Other studies have found that near complete or 
moderate tumour response is associated with improved survival.88,92 One study found a positive 
association only in cStage III patitens.97 Other studies found a more stepwise relationship in all 
TRG-grades, with better survival in higher TRG.91,291 Further, one study with focus on the near 
pCR patients concluded that these patients have at a higher risk for recurrence than expected.95 
The results from the Stockholm III trial indicates that patients with TRG 3 does not have the same 
excellent outcomes as patients with TRG 4/pCR. This might have implications in decisions on 
follow up or adjuvant treatment decisions. 
One issue with this study is the long inclusion period. The way surgical specimens have been 
handled, dissected and prepared for microscopic examination have changed during the years. 
However, this effect is seen in all three randomisation arms and is not likely to affect the relative 
estimates. One strength in the study is that all slides have been assessed by one pathologist, which 
removes the interindividual variation. This have in other settings have been proven to be a major 
problem.89 
Oncological outcomes and survival 
In Study I and IV, OS, RFS, incidences of LR and DM were not statistically different between the 
arms. There are some limitations in these estimates. First, the excellent incidence of LR make the 
non-inferiority design problematic. The initial upper CI-limit to deem non-inferiority (HR=1.7) 
was included in the CI of the point estimate. However, this was anticipated early after trial start 
and was accepted in the protocol amendment. The final conclusion regarding LR in the long-term 
follow up of the Stockholm III is that we are 90 % confident that SRT-delay is not 2.6 times worse 
than SRT. Under other circumstances this would might not be accepted as a decent level to claim 
non-inferiority. However, with the low levels of LR of today, the sample size needed to deem non-
inferiority at the 1.7 level, would be considerably higher compared to the Stockholm III trial.  
When analysing DM, the results are very similar in SRT and SRT-delay. Regarding OS and RFS 
there is a tendency of better outcomes in SRT-delay than in SRT, however not reaching statistical 
significance. RFS was chosen as one of the survival outcomes and not DFS, suggested by Punt et 
al.274 To calculate DFS, data on second cancers are needed which are not registered in the SCRCR. 
These results are on average in the whole cohort and there might be subgroups of patients with 
deviating outcomes. 
Is it safe to delay surgery? 
In these four papers we have shown that a delay to surgery has potential benefits. Post-operative 
complications are reduced and there is chance of downstaging and even pCR. The oncological 
outcomes in terms of LR, DM and survival are similar in the arms. However, there are some 
arguments against delaying surgery. First, in patients without tumour regression – TRG 0, the OTT 
is prolonged without any obvious gain. It is not easy to decide if this delay is harmful or not. 
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Patients with TRG 0-2 have inferior OS and TTR compared to patients with TRG 4. Many of 
the patients with high grade TRG also have longer OTT. In a supplementary analysis we included 
patients only with a delay to surgery, with the ambition to include only patients “at risk” for 
tumour regression. This did not change the results in a major way. TRG 0-2 was still associated 
with worse outcomes and this is probably due to different tumour biology. Further analyses of 
the effect of delaying surgery in subgroups based on tumour regression is not possible. The 
outcome is an effect of the exposure (delayed surgery). Second, patients that are considered for 
post-operative adjuvant treatment will have their start of chemotherapy delayed with several 
weeks. A possible negative effect on oncological outcomes in these patients, cannot be neglected. 
However, as discussed previously, the use of adjuvant chemotherapy in RC is controversial. 
On the other hand, the interval between RT and surgery might be useful. There is time to optimise 
patients before surgery. Interventions of interest include smoking cessation, adjustment of 
cardiovascular medication, physical exercise and other types of prehabilitation. Further, logistic 
planning might be facilitated by a longer OTT, when it is possible to plan patients to certain 
procedures such as laparoscopic, robotic or open resections. 
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FUTURE PERSPECTIVES│51 
Future perspectives 
During the last decades, outcomes for patients with RC have improved. Better preoperative 
staging, neo-adjuvant (C)RT and improved surgical technique have made it possible to achieve LR 
frequencies <5%. With modern intensive care and surgical technology perioperative mortality is 
rare. Some topics are however still of scientific interest. 
Patient selection 
There are evolving evidence that organ preserving strategies are safe and well tolerated.164,292 This 
has many implications for further research. One of the major questions are if we should irradiate 
more or less. In Sweden Watch and Wait (W&W) programs are based on cherry-picking, i.e the 
indications of RT are not changed. Patients with a near CR might enter a W&W program, all other 
will follow the standard program, which in most cases equals TME-surgery. The risk of expanding 
the indication for RT constitutes of overtreatment in patients without a cCR. In the new Swedish 
guidelines, the opposite direction is chosen (work in progress). The indication of RT is more 
restricted and fewer patients will receive neo-adjuvant RT. A study on choosing pathway would be 
interesting. The STAR-TReC trial, where patients are randomised to TME-surgery or organ-
preserving strategy, is an interesting approach to deal with this issue.  
In contrast to picking the winners, prediction of RT-response would be of most value. Focus has 
been on finding patients with excellent response, without finding any good predictive markers. 
Another approach might be to find patients with little probability of response, to be able to find a 
group of patients where RT can be avoided and/or to keep the OTT as short as possible. 
Quality of Life 
In the Stockholm III trial the median OS was about 10 years. With increasing survival, it is 
important to assure that all treatments are evaluated in the aspect of QoL. Patients without 
recurrences in the Stockholm III trial have been assessed by telephone interviews and 
questionnaires regarding QoL, and data is currently being analysed.  
Tumour regression 
At least two aspects of TRG assessment are important future research topics. First, the TRG 
assessment by MRI as an evaluation of treatment. MRI is now used as a screening tool to determine 
if patients are eligible for W&W programs or if surgery should be performed instead. It is important 
that radiologists and surgeons to have knowledge about the MRI, clinical and endoscopic findings 
in patients with potential cCR. Most data and reports come from highly specialised centres around 
the world. Today in Sweden, eligible patients are recommended to be referred to expert centres. 
However, the first screening is done at local hospitals, and the implementation of such practice 
much be followed by a scientific evaluation. Second, postoperative TRG-assessment suffers from 
large inter-individual variations. An attempt to minimise this has been presented by the 
pathologists in Leeds. The method is not yet fully published, but previous data indicates that the 
proportion of tumour cells in relation to stroma may predict survival.293 In short, the aim of the 
method is to decide the percentage of viable tumour cells using a digitalised assessment of the 
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“tumour density”. Some of the histopathological slides from patients in the Stockholm III trial 
have been examined and results are currently being analysed. 
Radiation techniques 
Technologies around RT are constantly being evolved including, MRI-based dose-planning, 
VMAT (volume based arc therapy), modern linear accelerators and proton radiation. These new 
techniques have the possibility of more effective RT with less acute and long term toxicity. 
Implementation of these techniques must be correlated with clinical outcomes in patients, and in 
collaboration with surgeons operating these patients. 
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Conclusions 
Overall conclusion 
Delaying surgery with 4-8 weeks after SRT in patients with RC appears safe regarding oncological 
outcomes and survival, with reduced number of post-operative complications. No benefits were 
found in LRT-delay. 
Specific conclusions 
- There were significantly less post-operative complications in SRT-delay compared to SRT. 
Radiation induced toxicity was seen in about 6-7 % in both the arms with a delay to surgery. 
The frequencies of LR were low, irrespective of allocated treatment. There were no 
statistically significant differences in the incidences of LR or DM in the arms. RFS and OS 
were similar in the arms. 
- The lowest risk of post-operative complications was seen in the group with longest OTT 
(5-13 weeks) after SRT. There were no obvious advantages with surgery very early in the 
short interval after SRT. 
- SRT-delay induces tumour regression and pCR more effectively compared to SRT and 
LRT-delay. pCR or TRG-4 are associated with improved OS and TTR. 
- In the long-term follow up of Stockholm III, there were no statistically significant 
differences in the cumulative incidence of local- or distant recurrence. Median OS (95 % 
CI) was 8.14 (7.23-9.98), 10.18 (8.45-11.68) and 10.53 (6.95-11.34) years in SRT, SRT-delay 
and LRT-delay respectively, without statistically significant differences between the groups.
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Sammanfattning på svenska 
Tjock och ändtarmscancer drabbar mer än 6000 personer/år i Sverige och är den näst vanligaste 
cancerformen hos både män och kvinnor. Ca 1/3 av fallen är ändtarmscancer, vilket innebär att 
tumören sitter på mindre än 15 cm avstånd från ändtarmsöppningen. Den viktigaste 
behandlingsformen för att uppnå bot är kirurgi. Operationen innebär oftast omfattande bukkirurgi 
där hela, eller del av ändtarmen tas bort tillsammans med omkringliggande blod- lymfkärl och 
lymfknutor. Det finns två dominerande operationstyper. Antingen kan man rekonstruera 
tarmkontinuiteten genom en skarv – anastomos. Om detta inte är möjligt för att tumören växer 
för nära ändtarmsöppningen görs en s.k. rektumamputation som innebär att även 
ändtarmsöppningen opereras bort. I dessa fall måste en permanent stomi anläggas. Den relativa 3 
årsöverlevnaden är 87 % hos patienter utan fjärrspridning (metastaser). Det är känt att risken för 
lokalrecidiv kan minskas med omkring hälften om strålbehandling ges innan operation, s.k. 
neoadjuvant radioterapi. Strålbehandling kan delas upp i många små enheter (fraktioner) eller färre, 
större fraktioner. Varje fraktions absorberade strålningsdos mäts i enheten Gray (Gy). 
Denna avhandling belyser väntan till kirurgi efter olika typer av strålbehandling vid 
ändtarmscancer. Grunden till arbetet är Stockholm III studien. En stor multicenter studie som 
mellan 1998-2013 lottade 840 patienter till tre olika strålbehandlingsregimer. 
SRT  5 stråltillfällen á 5 Gy och operation inom 1 vecka. 
SRT-delay 5 stråltillfällen á 5 Gy och operation efter 4-8 veckor. 
LRT-delay 25 stråltillfällen á 2 Gy och operation efter 4-8 veckor. 
Samtliga patienter har följts upp i det Svenska KoloRektalCancerRegistret. 
I arbete I analyserades samtliga patienter i studien efter att de följts i minst 2 år efter operation. 
De utfall som analyserades var akut strålningsbiverkan, postoperativa komplikationer, tid till 
lokalrecidiv, metastaser, total överlevnad och sjukdomsfri- överlevnad. Resultaten visade att SRT-
delay och LRT-delay hade ungefär lika stor andel patienter som behöver sjukhusvård till följd av 
strålningsbiverkan, ca 6-7 %. I grupperna med väntan till kirurgi var det lägre andel patienter som 
drabbades av någon komplikation efter kirurgin. Skillnaden var störst och statistiskt säkerställd när 
man jämförde SRT och SRT-delay. Andelen som fick lokalrecidiv var mycket låg och det fanns 
inga skillnader mellan behandlingsarmarna. Total- och sjukdomsfri överlevnad var lika i armarna. 
Konklusionen var att det är säkert att fördröja kirurgin efter strålbehandling med dessutom 
minskad risk för postoperativa komplikationer. 
Arbete II studerade de postoperativa komplikationerna i detalj. Syftet var att studera om det fanns 
några tidsintervall som kunde kopplas till extra bra eller dåliga utfall. Gruppen som fått kort 
strålbehandling (5 Gy x 5) delades upp i fyra grupper baserat på den totala behandlingstiden mellan 
strålstart och operation. Grupp A: 7 dagar, Grupp B 8-13 dagar, Grupp C 5-7 veckor och Grupp 
D 8-13 veckor. Resultaten visade att den minsta risken för komplikationer fanns i gruppen med 
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längst väntan till kirurgi, Odds Kvot någon komplikation, Grupp D vs. Grupp B (95 % Konfidens 
Intervall): 0.39(0.23;0.65) p<0.001, efter att ha justerat för störfaktorer. 
I arbete III analyserades de bortopererade tumörernas svar på strålning. Det är möjligt under 
mikroskopiundersökningen att gradera hur mycket en tumör har krympt ihop efter 
strålbehandling. En 5 gradig skala användes. 0 – Inget tumörsvar alls, 1 – dominerande tumörmassa 
utan ärrbildning, 2-dominerande ärrvävnad med endast lite tumörceller, 3- väldigt få tumörceller, 
4- inga kvarvarande tumörceller endast ärrvävnad. Samtliga tillgängliga operationspreparat har 
eftergranskats av en patolog som inte visste vilken typ av behandling patienten hade fått. Resultaten 
visade att SRT-delay var den grupp som hade störst sannolikhet att ha tumörer med komplett 
tumörsvar (TRG 4), vilket skedde i ca 10 % av fallen. Patienter som hade komplett tumörsvar hade 
en klart förbättrad överlevnad och mindre risk för canceråterfall (både lokalt och metastaser) 
jämfört med grupperna som hade TRG 0-2. 
Syftet med arbete IV var att studera långtidsutfallen i de olika behandlingsarmarna i Stockholm 
III studien. Data på återfall och överlevnad hämtades ånyo från registret när samtliga patienter 
följts i minst 5 år från kirurgi. Resultaten i arbete I bekräftades. Alltså, inga statiskt säkerställda 
skillnader avseende lokalrecidiv, metastaser eller överlevnad hittades mellan armarna. Total 
medianöverlevnaden i armarna (95 % konfidensintervall) var: SRT 8.14 år (7.23-9.98), SRT-delay 
10.18 år (8.45-11.68) , LRT-delay 10,53 år(6.95-11.34) 
Sammanfattningsvis framstår det säkert att fördröja kirurgi efter 5 Gy x 5. De postoperativa 
komplikationerna kan minska, men till priset av akuta strålningsbiverkningar. Om kirurgin fördröjs 
4-8 veckor efter strålning kan ca 10 % av tumörerna helt försvinna, dessa patienter har bättre 
överlevnad än övriga. 
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